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Liver is the central metabolic organ and performs many functions necessary for survival. 
Hepatocyte Nuclear Factor 4 alpha (HNF4a) is a nuclear receptor well characterized for its role 
in embryonic hepatocyte differentiation and maintenance of the adult hepatocyte phenotype. 
HNF4a regulates genes involved in many basic hepatocyte functions and deletion or decreased 
expression of HNF4a results in impaired liver function. More recently, HNF4a has been shown 
to exhibit tumor suppressor activity and deletion of HNF4a results in hepatocyte proliferation. 
The objectives of these studies were to characterize the role of hepatic HNF4a in hepatocyte 
proliferation and metabolism during liver regeneration and to harness HNF4a activity as a 
prognostic tool in liver cancer. 
 
The remarkable ability of liver to regenerate is possible due to the innate proliferative potential 
of quiescent adult hepatocytes. Knowing the role of HNF4a in maintaining hepatocyte function 
and suppressing hepatocyte proliferation, we hypothesized that HNF4a activity and expression 
may be adjusted to navigate hepatocytes between proliferative and quiescent states during liver 
regeneration. Using the partial hepatectomy model of liver regeneration, we identified decreased 
HNF4a activity in livers during the initiation of hepatocyte proliferation. Overexpression of 
HNF4a delayed hepatocyte proliferation after partial hepatectomy, and we identified Src-kinase 
as a potential regulator of HNF4a during the initiation of regeneration. Hepatocyte-specific 
deletion of HNF4a in mice (HNF4a-KO mice) resulted in 100% mortality after partial 
hepatectomy. RNA-Seq analysis of livers from these mice revealed significant dedifferentiated, 
and increased activation of proliferative and carcinogenic pathways. Our results show that 
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HNF4a is required to prevent hepatic failure after liver regeneration, is a critical regulator of 
termination of regeneration and provide new understanding of HNF4a position in regenerative 
networks. 
 
Downregulation of HNF4a has been well recognized in the progression of liver disease. We 
hypothesized that HNF4a activity could be used in the diagnosis and prognosis of liver diseases. 
Under the assumption that HNF4a activity could best be quantified by its target gene 
transcription, we identified a set of 44 genes by selecting only those genes that were direct 
HNF4a targets which were differentially regulated between WT and HNF4a-KO livers in 
normal and in liver tumors. qPCR analysis was used to validate the signature in mouse models of 
HNF4a deletion and liver cancer. Using this method, we detected lower HNF4a activity in 
human cirrhotic samples when compared to HCC samples. While no correlation was observed 
between disease state and the HNF4a staining pattern in diseased human tissues, the signature 
was able to accurately classify the severity of samples based on HNF4a activity. Further in silico 
analysis using human datasets confirmed the signatures ability to diagnose the severity of disease 
according to HNF4a activity. Lastly, when this analysis was performed on a dataset of human 
cirrhotic samples, we observed increased survival in a subset of cirrhotic samples with high 
HNF4a activity as determined by the signature. 
 
The role of HNF4a in regulating carbohydrate and lipid metabolism has been well studied, but 
how it effects overall global metabolism is not known. We used indirect calorimetry to examine 
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changes in energy expenditure and substrate utilization between WT and HNF4a-KO mice in 
fed, fasted, and high fat diet-fed conditions. We observed significant decreases in energy 
expenditure in HNF4a-KO mice during fed conditions which were exacerbated during high fat 
diet feeding. The changes were accompanied by significant adipose depletion and hypoglycemia. 
Our findings bring focus to the central role of liver in metabolism, which is largely regulated by 
hepatocyte HNF4a.  
 
Altogether, these studies indicate that hepatic HNF4a is a critical regulator of liver regeneration 
and global metabolism. Further, hepatic HNF4a activity can be used as a prognostic tool in 
chronic liver diseases such as cirrhosis and cancer. 
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Chapter 1. Introduction 
Portions of this chapter have been submitted and accepted for publication December 5, 2018. 
Huck, I., Gunewardena, S., Espanol-Suner, R., Willenbring, H., & Apte, U. (2018). Hepatocyte 
Nuclear Factor 4 alpha (HNF4alpha) Activation is Essential for Termination of Liver 
Regeneration. Hepatology. doi:10.1002/hep.30405 
Portions of this chapter have been previously published as a preprint and have not been peer-
reviewed. Huck, I., Morris, E. M., Thyfault, J. P., & Apte, U. (2018). Hepatocyte-Specific 
Hepatocyte Nuclear Factor 4 alpha (HNF4α) Deletion Decreases Resting Energy Expenditure By 
Disrupting Lipid and Carbohydrate Homeostasis. bioRxiv, 401802. doi:10.1101/401802 
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1.1. Introduction to HNF4a 
1.1.1. Highly conserved nuclear receptor 
Hepatocyte Nuclear Factor 4 alpha (HNF4a) is a zinc finger containing nuclear receptor first 
discovered bound to the transthyretin (TTR) and apolipoprotein CIII (apoCIII) promoter in rat 
liver extracts (Sladek, Zhong, Lai, & Darnell, 1990). Evidence from simple metazoans like 
trichoplax, coral and sponges suggest that HNF4a is one of the oldest nuclear receptors 
conserved during evolution (Baker, 2008; Grasso et al., 2001; Larroux et al., 2006). HNF4a is 
expressed by all animals (Sladek, 2011), and its DNA binding motifs are highly conserved in 
livers of chickens, opossums, dogs, mice and humans (Schmidt et al., 2010). HNF4a binds as a 
homodimer (Chandra et al., 2013) to direct repeat elements within the genome (Fang, Mane-
Padros, Bolotin, Jiang, & Sladek, 2012). Functional targets of HNF4a are conserved between 
mice and humans (Boj et al., 2009). 
 
Reports have shown that myristic acid can bind the HNF4a ligand binding domain (LBD) in 
HNF4a protein synthesized by bacteria (Dhe-Paganon, Duda, Iwamoto, Chi, & Shoelson, 2002) 
and linoleic acid can bind HNF4a in mammalian cells and mouse liver during fed, but not fasted 
conditions (Yuan et al., 2009). However, binding of these fatty acids does not significantly alter 
HNF4a transcriptional activity. Instead, the authors suggest binding may increase the structural 
integrity and half-life of the HNF4a protein. The discovery of a strong agonist or antagonist of 
HNF4a remains elusive. 
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1.1.2. HNF4a isoforms 
Multiple isoforms of HNF4a are produced from 2 promoters and the splicing of RNA and 
protein. In liver, a P2 promoter activates transcription of fetal HNF4a during embryonic liver 
development. After birth, the P2 promoter is silenced and a P1 promoter activates transcription 
of adult HNF4a isoforms (Torres-Padilla, Fougere-Deschatrette, & Weiss, 2001). The P2 
promoter is activated by HNF6 and HNF1 during embryonic liver development. Expression of 
adult HNF4a expression slowly increases throughout embryonic development until a certain 
threshold, at which point adult HNF4a isoforms silence the P2 promoter in adult liver (Briancon 
et al., 2004). 
 
The activity of fetal and adult HNF4a isoforms are similar but distinct. Adult and fetal HNF4a 
isoforms exhibit differential interaction with proteins including CBP, GRIP-1, p300, SMRT and 
HDACs due to differences in activation function domains between the isoforms (Torres-Padilla, 
Sladek, & Weiss, 2002). In colorectal cancer cells, P1-driven and P2-driven HNF4a isoforms 
can bind to different DNA binding motifs, associate with different coactivators and interact with 
other signaling pathways in a unique manner resulting in mainly tumor suppressor activity from 
adult isoforms and primarily growth promoting activity from fetal HNF4a (Vuong et al., 2015). 
While expression of fetal and adult HNF4a isoforms are mutually exclusive in normal liver, both 
isoforms are expressed in the colon where adult isoforms are primarily expressed in the 
differentiated colonic crypt and fetal isoforms are expressed in the proliferative compartment. 
Transgenic mice expressing exclusively fetal isoforms develop colitis and are at higher risk of 
developing colon cancer (Chellappa et al., 2016). In the pancreas, P2-driven HNF4a is 
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exclusively expressed (Harries et al., 2008; Tanaka et al., 2006) and P2 isoforms are required for 
proliferation and expansion of b-cells (Gupta et al., 2007). Moreover, overexpression of P2-
driven HNF4a is sufficient to initiate cell cycle in human b-cells (Rieck et al., 2012). In human 
hepatocellular carcinoma (HCC), adult HNF4a isoform expression is negatively correlated with 
fetal isoform expression. HCCs expressing high levels of fetal isoforms are associated with 
decreases survival compared to HCCs with high adult isoform expression (Cai, Lu, Liu, Zhang, 
& Yun, 2017). 
 
1.2. The Role of HNF4a in Embryonic Liver Development 
HNF4a is considered a marker of hepatocyte differentiation. However, its pro-differentiation 
activity exists long before hepatocytes develop. Examination of differentially expressed genes 
between different stages of early zygote division have shown that upregulation of networks 
activated by HNF4a are important for the first division of a single celled zygote (Godini & 
Fallahi, 2018), although this study did not investigate HNF4a mRNA or protein expression. 
However, HNF4a is considered to be a marker of primary endoderm since HNF4a mRNA can 
be detected in primary endoderm at embryonic day 4.5. HNF4a mRNA expression occurs in 
liver diverticulum and hindgut at day 8.5 and later in the mesonephric tubules, pancreas, 
stomach, intestine, and metanephric tubules (Duncan et al., 1994).  Homozygous loss of HNF4a 
is embryonically lethal due to impaired gastrulation (Chen et al., 1994), and complementation of 
HNF4a into HNF4a null embryos restores HNF4a expression in the visceral endoderm and 
rescues gastrulation (Duncan, Nagy, & Chan, 1997). A later study using this same model system 
showed that while HNF4a is not required for hepatic specification or the formation of 
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hepatoblasts, it is required for hepatic expression of gene critical for liver function (albumin, 
apolipoproteins, aldolaseB, PAH, LFABP, TFN RBP, EPO) as well as the transcription factors 
HNF1a and PXR (J. Li, Ning, & Duncan, 2000). Livers of hepatoblast-specific HNF4a-KO 
embryos (generated using alpha fetoprotein-CRE) showed significant disruptions in cell shape 
and lobule structure, likely caused by decreased expression of E-cadherin and gap junction 
proteins. These mice also exhibited decreased hepatic glycogen. HNF4a is required for 
establishing expression of other hepatic transcription factors (HNF1a, HNF1b, FOXA2, HNF6, 
LRH1, FXR, PXR) (Kyrmizi et al., 2006). Expression of HNF4a is also important for 
commitment of hepatoblasts to a hepatocyte lineage rather than a cholangiocyte lineage (Zaret & 
Grompe, 2008). For example, TBX3 suppresses cholangiocyte differentiation through activation 
of HNF4a (Ludtke, Christoffels, Petry, & Kispert, 2009) and suppression of HNF4a by 
overactivation of Hippo signaling results in expansion of biliary epithelial cells in livers  (Lee et 
al., 2016). 
 
1.3. The Role of HNF4a in Hepatocyte Differentiation and Liver Function 
1.3.1. HNFa and the hepatic transcription factor network 
The hepatic transcription factor network (HNF4a, HNF1a, HNF1b, FOXA2, HNF6, LRH1, 
FXR, PXR) is established by HNF4a in mice during embryonic liver development. Deletion of 
HNF4a during hepatic specification significantly disrupts the network, and HNF4a contributes 
to the stability of the network in adult hepatocytes (Kyrmizi et al., 2006). Studies in human 
hepatocytes have also confirmed HNF4a as a central regulator of the hepatic transcription factor 
network. Examination of the regulatory network circuitry motifs of six transcription factors 
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known to be important in hepatocyte biology (FOXA2, HNF4a, HNF1a, HNF6, CREB1, 
USF1), showed extensive autoregulation, with 5 of the 6 transcription factors binding their own 
promoter and multiple examples of each transcription factor binding to the promoter of the other 
transcription factors, resulting in several direct and indirect feed-forward activation loops. In the 
network examined, HNF4a exerted the most efferent connections to other members of the 
network. Combinatorial binding of multiple transcription factors at the same promoter was 
observed, with a significant enrichment in the number of target gene promoters bound by two or 
more regulators (Odom et al., 2006). Multiple transcription factors binding the same promoter 
leads to synergistic activation of gene expression and is important for maintaining tissue-specific 
gene expression (Costa, Kalinichenko, Holterman, & Wang, 2003). Some members of this 
network are also involved in pancreatic b-cell gene regulation (HNF4a, HNF1a, HNF6) and 
expression of P1-driven HNF4a in hepatocytes results in major differences in network activity 
compared to the pancreas, where P2-HNF4a is expressed (Odom et al., 2004). Decreased 
activity of the network (HNF1a, FOXA2, CEBPa, CEBPb, PPARa) has been associated with 
chronic hepatic failure (Guzman-Lepe et al., 2018) and decompensation of cirrhotic livers (T. 
Nishikawa et al., 2015). Temporary expression of HNF4a in these livers is enough to restore 
network activity leading to feed-forward activation of HNF4a and recovery of normal hepatic 
function (T. Nishikawa et al., 2015). 
 
1.3.2. HNF4a in hepatocyte differentiation and liver zonation 
In addition to its role in embryonic liver differentiation, HNF4a is critical for many important 
hepatic functions in adult liver, deeming it the master regulator of hepatocyte differentiation. 
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HNF4a is required for expression of Ornithine Transcarbamylase (OTC) and argininosuccinate 
lyase (ASL), which are involved in ureagenesis. HNF4a-KO mice have decreased serum urea 
and increased serum ammonia (Y. Inoue, Hayhurst, Inoue, Mori, & Gonzalez, 2002). In mouse 
models of a1-antitrypsin (AAT) deficiency, accumulation of mutated AAT in the liver is 
associated with decreased HNF4a expression and defective ureagenesis (Piccolo et al., 2017). 
HNF4a is also required for the synthesis of transferrin and transferrin receptor 2 which leads to 
hypoferremia (Matsuo et al., 2015). Synthesis of coagulation factors is dependent on HNF4a and 
clotting time is prolonged in HNF4a-KO mice (Y. Inoue, Peters, Yim, Inoue, & Gonzalez, 
2006). Activation of CYP3A4 by PXR or CAR requires HNF4a (Tirona et al., 2003). HNF4a 
binds the promoter and activates expression of CYP2C9 and CYP2C19 (Kawashima, 2006). 
siRNA knockdown of HNF4a in primary human hepatocytes decreases expression of drug 
metabolizing enzymes and transporters (CYP1A1, CYP2A6, CYP2B6, CYP2C8, CYP2C9, 
CYP2C19, CYP2D6, CYP2J2, CYP3A4, SULT2A1, UGT1A1, UGT1A9, ABCB1, ABCB11, 
ABCC2, OATP1B1, OCT1) (Kamiyama et al., 2007). Deletion of HNF4a from hepatocytes in 
mice disturbs expression of many hepatic phase II enzymes (SULT1A1, SULT1B1, SULT1e1, 
SULT2a2, SULT5a1, PAPSS1, UGT1a1, UGT1a5, UGT1a9, UGT2a3, UGT2b1, UGT2b36, 
UGT3a1, UGT3a2, GSTa4, GSTM1, GSTM2, GSTM4, GSTM6, GSTP2), uptake transporters 
(NTCP, OATP1a1, OATP1a4, OATP1b2, OATP2b1, OAT2, OCT1, OCTN2, SAT1, NPT1, 
SVCT1) and efflux transporters (MRP3, MRP6, BCRP, MDR1a, MATE1) (Hayhurst, Lee, 
Lambert, Ward, & Gonzalez, 2001; Lu, Gonzalez, & Klaassen, 2010). The role of HNF4a in 
regulation of drug metabolizing enzymes and transporters has been extensively reviewed 




Studies show that HNF4a is involved in the maintenance of liver zonation by suppressing 
pericentral genes in periportal hepatocytes (Stanulovic et al., 2007) and activation of Wnt/b-
catenin displaces HNF4a in liver stem cells allowing them to take on a pericentral phenotype 
(Colletti et al., 2009). This mechanism is also observed in AAT, when activation of b-catenin 
and decreased expression of HNF4a perturbs liver zonation (Piccolo et al., 2017). 
 
1.3.3. HNF4a and bile acid metabolism 
Hepatic functions related to bile acid metabolism are heavily HNF4a dependent. HNF4a-KO 
mice have increased serum bile acid levels, decreased hepatic bile acid import, decreased fecal 
bile acid excretion, increased urinary bile acid excretion, and decreased overall bile acid 
synthesis. This is due to decreased expression of several enzymes involved in bile acid 
metabolism including CYP7A1, CYP7B1, CYP8B1 and CYP27A1 (Hayhurst et al., 2001; Y. 
Inoue, Yu, et al., 2006). HNF4a binding at promoter and enhancer elements results in increased 
CYP7A1 expression, but PXR activation can inhibit CYP7A1 expression by binding HNF4a and 
disrupting the transcriptional complex (T. Li & Chiang, 2005). Similarly, PROX1 inhibits 
CYP7A1 expression by binding to HNF4a at its AF-2 domain (K. H. Song, Li, & Chiang, 2006). 
CDCA and IL-1b can inhibit CYP7A1 expression by activating JNK signaling which decreases 
HNF4a expression leading to decreased PGC1a and HNF4a occupancy of CYP7A1 promoter 
(T. Li, Jahan, & Chiang, 2006). TGFb can activate SMAD3 and HDACs to epigenetically 
silence the CYP7A1 promoter. In this mechanism, SMAD3 directly interacts with HNF4a (T. Li 
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& Chiang, 2007). Glucose-induced activation of AMPK decreases HNF4a protein, but induces 
CYP7A1 expression by increasing promoter acetylation (T. Li, Chanda, Zhang, Choi, & Chiang, 
2010). Expression of bile acid conjugating enzymes (BAT, VLACSR) is HNF4a-dependent, 
with HNF4a-KO mice exhibiting increased levels of unconjugated bile acids (Y. Inoue, Yu, 
Inoue, & Gonzalez, 2004). HNF4a binds the promoter and activates CSAD, an enzyme involved 
in taurine synthesis. SHP activation will suppress CSAD expression by binding to HNF4a in the 
CSAD promoter (Y. Wang, Matye, Nguyen, Zhang, & Li, 2018). This same method of 
regulation also occurs on the promoter of CYP7A1, with HNF4a and LRH1 activating CYP7A1 
expression and SHP targeting HNF4a on the CYP7A1 promoter to suppress transcription (Kir, 
Zhang, Gerard, Kliewer, & Mangelsdorf, 2012). CYP7A1 is also suppressed when HNF4a is 
inhibited after phosphorylation by PKA (Yan et al., 2017). HNF4a coactivates bile acid 
synthesis genes with other transcription factors, including CAR, EGR1 and C/EBPa to activate 
CYP2B6 (Benet, Lahoz, Guzman, Castell, & Jover, 2010; K. Inoue & Negishi, 2008). 
 
1.3.4. HNF4a and lipid and carbohydrate metabolism 
HNF4a plays a major role in hepatic lipid and carbohydrate metabolism. HNF4a-null drosophila 
larvae express lower levels of b-oxidation genes, and higher levels of lipid stores. These mutants 
also exhibit significant mortality after 24 hours of starvation (Palanker, Tennessen, Lam, & 
Thummel, 2009). Hepatocyte-specific HNF4a-KO mice exhibit hepatic steatosis and depletion 
of hepatic glucose (Hayhurst et al., 2001; Martinez-Jimenez, Kyrmizi, Cardot, Gonzalez, & 
Talianidis, 2010; Walesky, Edwards, et al., 2013). Decreased hepatic glycogen is caused by 
inhibited gluconeogenesis. HNF4a is induced during fasting and is required for activation of 
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gluconeogenic genes (PEPCK, G6Pase) by PGC-1a (Rhee et al., 2003; Yoon et al., 2001). Also, 
fructose-1,6-bisphosphatase is coactivated by HNF4a and C/EBPa (Wattanavanitchakorn, 
Rojvirat, Chavalit, MacDonald, & Jitrapakdee, 2018). Inhibition of HNF4a by DAX1 
(Nedumaran et al., 2009) and SULT2B1 (Bi et al., 2018) are mechanisms known to negatively 
regulate gluconeogenesis.  
 
b-oxidation is an important part of the fasting response. Expression of dominant negative 
HNF4a in rats decreases expression of CPT1 (Louet, Hayhurst, Gonzalez, Girard, & Decaux, 
2002). HNF4a is important for suppressing PPARa-mediated b-oxidation during fed conditions 
and is a direct activator of PPARa during fasted conditions (Martinez-Jimenez et al., 2010). 
HNF4a is also required for activation of PPARa by PI3K/AKT signaling (X. Yang et al., 2018). 
Accumulation of hepatic lipids and cholesterol in HNF4a-KO mice is likely caused by decreased 
expression of HNF4a target genes involved in VLDL synthesis and packaging (apolipoproteins, 
MTTP), and increased expression of hepatic HDL importer, CD36 (Hayhurst et al., 2001). This 
results in decreased serum triglycerides and cholesterol (Hayhurst et al., 2001; L. Yin, Ma, Ge, 
Edwards, & Zhang, 2011). A similar phenotype is observed in steatosis following HFD feeding 
where increased oxidative stress decreases APOB expression by promoting cytoplasmic 
translocation of HNF4a (Yu et al., 2018). Regulation of hepatic lipid homeostasis by HNF4a 
also occurs through epigenetic mechanisms. An examination of changes to open chromatin sites 
after high fat diet (HFD) feeding found that majority of sites were bound by HNF4a (Leung et 
al., 2014). Later, it was confirmed that HNF4a can recruit PROX1-HDAC3 to epigenetically 
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regulate genes which suppress steatosis. Deletion of HNF4a or this complex increased hepatic 
triglycerides (TG) (Armour et al., 2017).  
 
1.4. HNF4a and Proliferation 
1.4.1. Antiproliferative effects of HNF4a in hepatocytes and other cell types 
Recent studies have revealed that HNF4a is antiproliferative in several cell types including 
hepatocytes. Decreased expression of HNF4a is observed in human renal cell carcinoma (Sel, 
Ebert, Ryffel, & Drewes, 1996) and expression of HNF4a in HEK293 cells reduces proliferation 
(Lucas et al., 2005). HNF4a has also been shown to be antiproliferative in pancreatic B-cells 
(Erdmann et al., 2007), gastric epithelium (Moore, Khurana, Huh, & Mills, 2016) and the 
proliferative compartment of the colonic crypt (Chellappa et al., 2016). The antiproliferative 
effects of HNF4a may be limited to P1 isoforms. P2 HNF4a is associated with proliferation in 
pancreatic b-cell proliferation (Gupta et al., 2007; Rieck et al., 2012), colon cancer cells (Vuong 
et al., 2015), colon cancer (Chellappa et al., 2016), and hepatocellular carcinoma (S. H. Cai et al., 
2017). Hepatocyte-specific deletion of HNF4a in mice results in hepatomegaly and spontaneous 
hepatocyte proliferation, the product of increased Cyclin D1 expression (Bonzo, Ferry, 
Matsubara, Kim, & Gonzalez, 2012; Hayhurst et al., 2001; Walesky, Gunewardena, et al., 2013). 
One mechanism by which HNF4a exerts its antiproliferative effects is the activation of 
antiproliferative p21 gene (Chiba et al., 2005). HNF4a competes with oncogene c-Myc for a 
position on the p21 promoter (Hwang-Verslues & Sladek, 2008). Expression of HNF4a was 
decreased in fast-growing dedifferentiated HCC cell lines compared to slower growing cell lines 
exhibiting a more differentiated hepatocyte phenotype (Lazarevich et al., 2004). Combined with 
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the known role of HNF4a in hepatocyte differentiation and function, these data suggest HNF4a 
is a central regulator of hepatocyte function and quiescence.  
 
1.4.2. HNF4a during liver regeneration 
The liver exhibits enormous capacity to regenerate following surgical resection or chemical 
injury (Michalopoulos, 2017). Two-thirds partial hepatectomy (PH) is a long established model 
(Higgins & Anderson, 1931) used to study liver regeneration in a variety of species (Mortensen 
& Revhaug, 2011). After PH, adult hepatocytes enter cell division, undergo proliferation, and 
return to a quiescent state once the mass of the original liver has been reached (Malato et al., 
2011). This feature makes PH an excellent model for studying the innate proliferative potential 
of adult hepatocytes. Regulation of differentiation and proliferation during this process could 
both be regulated through modulation of HNF4a activity. No change in HNF4a mRNA has been 
detected after PH (Flodby et al., 1993), although HNF4a transcriptional activity is suppressed 4 
hours post-PH (Jiao, Zhu, Lu, Zheng, & Chen, 2015). One study has reported decreased staining 
of HNF4a in periportal hepatocytes after PH (Fukuda, Fukuchi, Yagi, & Shiojiri, 2016). 
However, these three studies contain the extent of what is known about HNF4a during liver 
regeneration. 
 
1.5. HNF4a and Liver Disease 
Extensive evidence exists showing the association between decreased HNF4a and the 
progression of liver disease. Downregulation of HNF4a protein and its transcriptional targets has 
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been shown to occur during the development of Non-alcoholic Fatty Liver disease (NAFLD) and 
Non-alcoholic steatohepatitis (NASH) (Baciu et al., 2017; Yu et al., 2018). Primary hepatocytes 
cultured on stiff matrix have decreased HNF4a network activity and dedifferentiation (Desai et 
al., 2016). Expression of HNF4a lessens the severity of fibrosis in rats treated with 
dimethylnitrosamine or bile duct ligation (Yue et al., 2010) and decreased HNF4a expression is 
correlated with advanced stages of fibrosis in humans (Guzman-Lepe et al., 2018).  
 
The progression of cirrhosis is also associated with downregulation of HNF4a. Adenoviral 
delivery of HNF4a reversed the severity of thioacetamide induced cirrhosis in rats by 
upregulating MMPs (Fan et al., 2013). The transcription factor WT1 can downregulate HNF4a 
in primary rat hepatocytes, is over expressed in cirrhotic human livers, and is negatively 
correlated with HNF4a expression in livers with advanced cirrhosis (Berasain et al., 2003). 
Finally, in rats treated with CCl4, loss of HNF4a expression occurred in rats with decompensated 
cirrhosis. This was associated with significant reductions in measures of hepatic function. 
Reexpression of HNF4a rescued rats with decompensated cirrhosis and restored stability of the 
hepatic transcription factor network (T. Nishikawa et al., 2015). This study demonstrated that 
destabilization of the hepatic transcription factor network results in loss of hepatic function 
leading to decompensation. 
 
Numerous studies have shown the role of HNF4a in promoting an epithelial phenotype 
(Battistelli et al., 2018; W. Y. Cai et al., 2017; Q. Huang et al., 2017; Ning et al., 2010; Parviz et 
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al., 2003; Santangelo et al., 2011). Likewise, there is significant evidence for HNF4a to function 
as a tumor suppressor in hepatocellular carcinoma. Numerous studies have shown decreased 
expression of HNF4a in human HCCs (W. Y. Cai et al., 2017; Hatziapostolou et al., 2011; Ning 
et al., 2014; Ning et al., 2010). Irregular staining of HNF4a isoforms has been observed in 
human HCC (Tanaka et al., 2006) and HCCs expressing high levels of fetal HNF4a exhibit the 
poorest prognosis (S. H. Cai et al., 2017). Studies from our lab show that deletion of HNF4a 
promotes the progression of HCC through c-Myc activation. HNF4a-KO mice exhibit higher 
tumor burden and increased size of tumors (Walesky, Edwards, et al., 2013). Decreased HNF4a 
expression is observed during the transition from cirrhosis to HCC in humans and mice (Ning et 
al., 2010). Forced expression of HNF4a in diethylnitrosamine mice from this study prevented 
the development of HCC by inhibiting b-Catenin signaling and increasing E-cadherin 
expression.  
 
HNF4a suppresses many procarcinogenic programs activation of these programs after inhibition 
of HNF4a is a common mechanism driving many HCCs. Human HCCs with an unmutated b-
catenin gene retain zone specific gene expression patterns, including gene expression maintained 
by HNF4a, exhibited decreased aggressiveness, are less advanced and showed longer survival. 
These findings contrasted with highly aggressive perivenous HCCs exhibiting overactive b-
catenin and suppressed of HNF4a transcriptional activity (Desert et al., 2017). Similarly, an 
inverse relationship between hippo signaling effector YAP and HNF4a was observed in human 
HCCs. Studies showed that YAP can activate proteasomal degradation of HNF4a while forced 
expression of HNF4a in mice downregulated YAP and slowed the progression of HCC (W. Y. 
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Cai et al., 2017). Temporary HNF4a inhibition is enough to permanently activate a positive 
feedback loop in which STAT3 inhibits HNF4a, resulting in HCC (Hatziapostolou et al., 2011). 
A negative feedback loop between NF-kB and HNF4a has been identified such that loss of 
HNF4a expression enhances NF-kB signaling in a model of HCC metastasis (Ning et al., 2014). 
HNF4a can impart its anti-tumor activity by affecting miRNA expression. HNF4a induces miR-
379-656 cluster to transcribes miR-134, which has tumor suppressor activity. HCCs exhibit 
decreased expression of HNF4a and miR-134 in tumor tissue compared to adjacent non-tumor 
tissue (C. Yin et al., 2013). 
 
This strong evidence for the role of HNF4a in inhibiting hepatic carcinogenesis has led many to 
test if restoration of HNF4a expression can be used as a treatment for HCC. Overexpression of 
HNF4a in Hepa1C1C cells causes cell cycle arrest (Walesky, Gunewardena, et al., 2013). 
Adenoviral delivery of HNF4a into Hep3B and HepG2 cells decreases expression of stem cell 
markers and prevents these cells from metastasizing to the liver when injected into mice (C. Yin 
et al., 2008). Overexpression of HNF4a blocked the formation of DEN-induced HCC in mice 
(Ning et al., 2010) The tumor suppressor activity of HNF4a is most likely due to its central role 
in maintaining stability of the hepatic transcription factor network. This was demonstrated when 
combined expression of HNF4a, HNF1a, and FOXA3 were more effective at inhibiting cancer 
cell proliferation than when just one of these transcription factors was expressed (Takashima, 
Horisawa, Udono, Ohkawa, & Suzuki, 2018). Treatment with the flavonoid, Oroxylin A, can 
indirectly restore HNF4a gene expression and slows HCC tumor growth and increases survival 
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in mice (Wei et al., 2017). However, while the potential of HNF4a activation for HCC therapy is 
great, direct agonists of HNF4a have not been developed. 
 
1.6. Purpose and Aims 
The role of HNF4a in hepatocyte differentiation and specific liver functions has been well 
established. However much remains to be understood about how the proliferative capacity of 
hepatocytes can be kept in check during normal conditions. It is also clear that loss of HNF4a 
activity is associated with the progression of liver disease and targeting HNF4a would be 
therapeutically beneficial in some cases, but techniques and tools to use this knowledge in a 
prognostic or diagnostic setting do not exist. Finally, although we know that a primary function 
of HNF4a is in hepatic carbohydrate and lipid homeostasis, it is not known how disruption of 
hepatic HNF4a effects metabolism beyond the liver. This would be especially important to know 
if HNF4a were to be therapeutically inhibited or activated. The main objective of this 
dissertation was to use novel models and techniques to further characterize the behavior of 
hepatic HNF4a in proliferation and metabolism and exploit its activity as a prognostic tool. 
Specific Aim 1: Investigate the role of HNF4a on hepatocyte regeneration 
• Examine expression and activity of HNF4a during liver regeneration after partial 
hepatectomy. 
• Determine the effect of HNF4a overexpression on initiation of liver regeneration after 
partial hepatectomy. 
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• Determine the effect of hepatocyte-specific HNF4a deletion on termination of liver 
regeneration after partial hepatectomy. 
We hypothesized that modulation of HNF4a expression and activity would be required to 
navigate hepatocyte between quiescent and proliferative states during liver regeneration after 
partial hepatectomy. Initiation of regeneration would require activation of proliferative pathways 
normally repressed by HNF4a. Termination of regeneration would require a return to quiescence 
by inhibiting proliferation and reestablishment of hepatocyte specific gene expression.  
 
Specific Aim 2: Develop HNF4a target gene signature to be used as a prognostic tool for HCC 
treatment 
• Identify genes to include in signature which robustly depict differences in HNF4a 
activity in normal and diseased conditions. 
• Validate this signature in human and mouse tissues. 
• Test the ability of the signature to determine disease progression or prognosis in human 
and mouse datasets. 
We hypothesized that decreased HNF4a activity, as measured by target gene expression, would 
directly correlate with progression of liver disease. We hypothesized that this knowledge could 
be used to accurately identify HCC advancement and potentially predict which cirrhotic patients 
would go on to develop HCC. 
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Specific Aim 3: Investigate the role of hepatic HNF4a on global metabolism 
• Characterize the effect of hepatic HNF4a deletion on whole body energy expenditure and 
substrate utilization. 
• Determine the role of HNF4a in regulating whole body metabolism in various metabolic 
challenges. 
We hypothesized that the well described role of HNF4a in hepatic carbohydrate and lipid 
homeostasis would have a significant effect on systemic energy expenditure and substrate 
utilization.  
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Chapter 2. Hepatocyte Nuclear Factor 4 alpha (HNF4a) Activation is 
Essential for Termination of Liver Regeneration 
Portions of this chapter have been submitted and accepted for publication December 5, 2018. 
Huck, I., Gunewardena, S., Espanol-Suner, R., Willenbring, H., & Apte, U. (2018). Hepatocyte 
Nuclear Factor 4 alpha (HNF4alpha) Activation is Essential for Termination of Liver 





Hepatocyte Nuclear Factor 4 alpha (HNF4a) is critical for hepatic differentiation. Recent studies 
have highlighted its role in inhibition of hepatocyte proliferation and tumor suppression. 
However, the role of HNF4α in liver regeneration is not known. We hypothesized that 
hepatocytes modulate HNF4α activity when navigating between differentiated and proliferative 
states during liver regeneration. Western blot analysis revealed a rapid decline in nuclear and 
cytoplasmic HNF4α protein levels accompanied with decreased target gene expression within 1 
hour after 2/3 partial hepatectomy (post-PH) in C57BL/6J mice. HNF4a protein expression did 
not recover to the pre-PH levels until day 3. Hepatocyte-specific deletion of HNF4a (HNF4α-
KO) in mice resulted in 100% mortality post-PH despite increased proliferative marker 
expression throughout regeneration. Sustained loss of HNF4α target gene expression throughout 
regeneration indicated HNF4α-KO mice were unable to compensate for loss of HNF4α 
transcriptional activity. Deletion of HNF4a resulted in sustained proliferation accompanied by c-
Myc and Cyclin D1 over expression and a complete deficiency of hepatocyte function after PH. 
Interestingly, overexpression of degradation-resistant HNF4a in hepatocytes delayed but did not 
prevent initiation of regeneration after PH. Finally, AAV8-mediated reexpression of HNF4α in 
hepatocytes of HNF4α-KO mice post-PH restored HNF4α protein levels, induced target gene 
expression and improved survival of HNF4α-KO mice post-PH. In conclusion, these data 
indicate that HNF4a reexpression following initial decrease is critical for hepatocytes to exit 
from cell cycle and resume function during the termination phase of liver regeneration. These 




The role of HNF4a in promoting hepatocyte differentiation and inhibiting hepatocyte 
proliferation was detailed in Chapter 1. Liver has a remarkable capacity to regenerate upon 
surgical resection, and following viral or drug-induced liver injury. During liver regeneration 
after 2/3 partial hepatectomy (PH), the most widely used model to study liver regeneration, 
multiple redundant mechanisms regulate initiation and termination of hepatocyte regeneration 
(Michalopoulos, 2017). Understanding the mechanisms that govern adult hepatocytes to navigate 
between quiescent and proliferative states could result in therapeutic targets for inducing 
hepatocyte proliferation during impaired regeneration or inhibiting excess proliferation during 
carcinogenesis. Despite its role in maintaining hepatocyte differentiation and quiescence, little is 
known about the role of HNF4a in hepatocyte regeneration or how decreased HNF4a, a 
condition commonly found in diseased human livers (W. Y. Cai et al., 2017; Hatziapostolou et 
al., 2011; T. Nishikawa et al., 2015; Tanaka et al., 2006), would impact regeneration. In this 
study, we investigated the role of HNF4a in regulation of liver regeneration after PH using 
wildtype (WT) and HNF4a-KO mice. Our studies revealed that HNF4a is indispensable for 
survival after PH and a critical component of termination of liver regeneration.  
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2.3. Materials and Methods 
2.3.1. Animal Care and Surgeries. 
Animals were housed in facilities accredited by the Association for Assessment and 
Accreditation of Laboratory Animal Care at the University of Kansas Medical Center under a 
standard 14-hr dark/10-hr light cycle with access to chow and water ad libitum. All studies were 
approved by the Institutional Animal Care and Use Committee at the University of Kansas 
Medical Center. PH surgeries were performed and tissue samples obtained as previously 
described (Borude et al., 2012). Surgeries were performed between 9:00 am and 11:00 am. For 
liver regeneration in normal conditions, two-month-old male C57BL6/J mice were euthanized at 
0, 1, 3, 6, 12, 24 and 48 hr, and 3, 5, 7, and 14 days after PH with 3 mice per time point. To test 
the effects of Src inhibition on nuclear HNF4a expression, C57BL6/J mice were injected with 
either the Src-specific inhibitor PP2 (Cayman Chemical, Cat. #13198) dissolved in 1% DMSO or 
vehicle for 4 days before undergoing PH surgeries. Mice were euthanized 6 hours post-PH and 
nuclear and cytoplasmic extracts were prepared from fresh liver. To study the effects of HNF4a 
deletion on liver regeneration, seven days before surgery HNF4a-floxed mice were injected 
intraperitoneally with AAV8-TBG-eGFP or AAV8-TBG-CRE resulting in WT and hepatocyte-
specific HNF4a-KO animals, respectively. These vectors were purchased from Penn Vector 
Core (Philadelphia, PA) and injected as previously described (Yanger et al., 2013). WT and 
HNF4a-KO mice were euthanized at 0, 1, 2, 5, 7 and 14 days after PH with 3-5 mice per group. 
Only two HNF4a-KO mice survived to be included at the 7-day time point. HNF4a reexpression 
was accomplished by tail vein injection of 2 x 1011 viral genomes/mouse of AAV8-CMV-
HNF4a generated in the laboratory of Dr. Holger Willenbring. Male HNF4a-floxed mice were 
injected with AAV8-TBG-CRE to induce HNF4a deletion and 7 days later were injected with 
 23 
AAV8-CMV-HNF4a to restore HNF4a expression. Liver and serum samples were collected 
seven days after AAV8-CMV-HNF4a injection. Next, this system was used to test if HNF4a 
reexpression could rescue HNF4a-KO mice after partial hepatectomy. WT and HNF4a-KO 
mice underwent PH 7 days after injection with AAV8-TBG-eGFP or AAV8-TBG-CRE with 
four mice per treatment. Tail vein injection with reexpression vector or control saline occurred 2 
days after surgery to allow for initiation of regeneration. Overexpression of HNF4a was 
accomplished using Tet-On-HNF4a transgenic mouse line developed at the KUMC Transgenic 
and Gene Targeting Institutional Facility. These mice contained a reverse tetracycline-controlled 
transcriptional activator which was constitutively expressed with a C/EBPb promoter. The 
existence of a possible feed forward activation loop of C/EBPb by HNF4a due to strong HNF4a 
ChIP signal on the C/EBPb promoter existed in this model (Schmidt et al., 2010). In the presence 
of the tetracycline-derivative Doxycycline (Dox), this transcription factor binds a tetracycline 
response element (TRE) upstream of an shRNA-resistant HNF4a gene (kind gift from Dr. 
Stephen A. Duncan, Medical University of South Carolina). Tet-On-HNF4a were heterozygous 
for both transgenes. Doxycycline was administered for two weeks prior to surgery by replacing 
drinking water with a 1 mg/mL Dox in 5% Sucrose solution. Untreated mice were given 5% 
sucrose solution only. Two mice were used for the untreated 6 hour time point and three to five 
mice used for all other treatments and time points.  
 
2.3.2. Protein Isolation and Western blotting. 
Nuclear and cytoplasmic lysates and RIPA extracts were prepared and used for Western blot 
analysis as reported (Wolfe et al., 2011). To visualize the extremely low levels of cytoplasmic 
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HNF4a, SuperSignal West Femto Maximum Sensitivity Chemiluminescent Substrate 
(ThermoScientific, Cat# 34095) was used. Primary antibodies are provided in Table 2.3.1. 
Densitometric analysis was performed using Image Studio Lite (LI-COR Biosciences).  
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Table 2.3.1: Catalog Numbers of Antibodies Used in This Study 
Antibody Catalog no. Manufacturer 
AKT 4691 Cell Signaling Technology 
Phospho-AKT (Ser473) 9271 Cell Signaling Technology 
b-actin 4970 Cell Signaling Technology 
b-Catenin 8480 Cell Signaling Technology 
Phospho-b-Catenin (Thr41/Ser45) 9565 Cell Signaling Technology 
CDK4 2906 Cell Signaling Technology 
Cyclin D1 2978 Cell Signaling Technology 
EGFR 4267 Cell Signaling Technology 
Phospho-EGFR (Tyr1045) 2237 Cell Signaling Technology 
ERK1/2 9102 Cell Signaling Technology 
Phospho-ERK1/2 Thr202/Tyr204) 4376 Cell Signaling Technology 
GAPDH 2118 Cell Signaling Technology 
GSK-3b 9315 Cell Signaling Technology 
Phospho-GSK-3b (Ser9) 9323 Cell Signaling Technology 
Histone H3 9717 Cell Signaling Technology 
Adult HNF4a isoforms PP-K9218-00 Perseus Proteomics 
All HNF4a isoforms PP-H1415-00 Perseus Proteomics 
c-Met 3127 Cell Signaling Technology 
c-Myc 5605 Cell Signaling Technology 
p38 8690 Cell Signaling Technology 
Phospho-p38 (Thr180/Tyr182) 4511 Cell Signaling Technology 




2.3.3. Real Time PCR. 
RNA isolation, conversion to cDNA and Real time PCR analysis was performed as previously 
described (Apte et al., 2009). HNF4a positive and negative target genes were identified based on 
RNA-Seq analysis comparing gene expression in livers from WT and hepatocyte-specific 
HNF4a-KO mice (Walesky, Edwards, et al., 2013).. Primer sequences are provided in Table 
2.3.2.  
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Table 2.3.2: Primer Sequences Used in This Study 
Gene Name Forward Primer (5' - 3') Reverse Primer (5' - 3') 
18s TTGACGGAAGGGCACCACCAG GCACCACCACCCACGGAATCG 
Akr1b7 TTCTGATTCGGTTCCATGTCC TCCAGTTCCTGTTGAAGCTG 
Alas2 TTTAGTATTGGACGCTGCCC CTTCCTGTCTTGGAGTTCTGAC 
ApoA2 GACACCCCTTGTCAGGTCAG TGGCACATCTCACTTAGCCG 
ApoB CTGCAACCAAGCTGGCATAAG CCTCCATCCTGAGTTGGACA 
c-Myc GCTGTTTGAAGGCTGGATTTC GATGAAATAGGGCTGTACGGAG 
CcnD1 GCCCTCCGTATCTTACTTCAAG GCGGTCCAGGTAGTTCATG 
Cdkn3 TCGGTTTATGTGCTCTTCCAG ATATTTTGACAGCTCCCCTCTG 
Ces3 TGTATGAGTTTGAGTATCGCCC CATCTTGCTGAGGTTGGTCT 
Cldn1 TCAGATGATGTTTTCCCGATGACCTTT AAGCACAGTTTGCAGGATCTGGGATG 
Cyp2c37 GATGGCAATCAACCATTGC GCCGATCACATGCTCAATT 
Defb1 AATACAAATGCCTTCAACATGGAG ATCCATCGCTCGTCCTTTATG 
Dio1 GTTGCACCTGACCTTCATTTC CCACGTTGTTCTTAAAAGCCC 
Ect2 CGTGTTACCATCTCCTTCTGAG TCACTCTTGCTTCAACCTGC 
Egr1 AGCGCCTTCAATCCTCAAG TTTGGCTGGGATAACTCGTC 
F12 GCCATTTTCCCTTTCAGTACC TCTTTCACTTTCTTGGGCTCC 
Hjurp AGTACAACCAGCCCTTTGAG GCCCATTTAATCTGTCAATCACC 
Hnf4a Adult 
Isoforms GAAAATGTGCAGGTGTTGACCA AGCTCGAGGCTCCGTAGTGTTT 
Slc34a2 CTGGGATCAAATGGTCAGAGAG GAGCACACGAACAAGTAGAGAA 




2.3.4. Staining Procedures. 
Paraffin-embedded liver sections (4-µm thick) were used for immunohistochemical staining of 
proliferating cell nuclear antigen (PCNA) as previously described(Borude et al., 2012). PCNA 
positive hepatocyte nuclei were quantified by counting three 40x fields per slide for each liver 
sample. 
 
2.3.5. Serum Bilirubin 
Total serum bilirubin was determined using the Total Bilirubin kit from Pointe Scientific (Cat 
#B7576) according to manufacturer’s protocol.  
 
2.3.6. RNA Sequencing and Ingenuity Pathway Analysis.  
Equal amounts of RNA was pooled using WT and HNF4a-KO livers (n=3) from day 5 and day 7 
post-PH to be used for RNA-Seq and Ingenuity Pathway Analysis (IPA). The Stranded mRNA-
Seq was performed using the Illumina HiSeq2500 Sequencing System at the University of 
Kansas Medical Center – Genomics Core (Kansas City, KS). Total RNA ( 0.5ug) was used to 
initiate the Stranded mRNA-Seq library preparation protocol. The mRNA fraction was enriched 
with oligo dT capture, sized, reverse transcribed into cDNA and ligated with the appropriate 
indexed adaptors using the TruSeq Stranded mRNA Sample Preparation Kit (Illumina RS-122-
2101/2102). Following Agilent Bioanalyzer QC of the library preparation and library 
quantification using the Roche Lightcycler96 with KAPA SYBR Fast Universal qPCR kit 
(KAPA Biosystems KK4601 ), the RNA-Seq libraries were adjusted to a 2nM concentration and 
pooled for multiplexed sequencing. Libraries were denatured and diluted to the appropriate pM 
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concentration (based on qPCR results) followed by clonal clustering onto the sequencing flow 
cell using the TruSeq Paired-End (PE) Cluster Kit v3-cBot-HS (Illumina PE401-3001). The 
clonal clustering procedure is automated using the Illumina cBOT Cluster Station.  The clustered 
flow cell was sequenced on the Illumina HiSeq 2500 Sequencing System using the TruSeq SBS 
Kit  v3-HS (Illumina FC401-3002). Following collection, sequence data is converted from .bcl 
file format to FASTQ files and de-multiplexed (if required) into individual sequences for further 
downstream analysis. RNA sequencing and bioinformatics analysis were performed as 
previously described in detail (Walesky, Edwards, et al., 2013). An absolute fold change cut off 
of 3 was used to quantify differentially expressed genes (Table 2.4.1) and to select genes used in 
Ingenuity Pathway Analysis (IPA, Ingenuity Systems). IPA was used to calculate activation z-
scores to predict activation or inhibition of upstream regulators and disease pathways 
 
2.3.7. Statistical Analysis 
Results are expressed as mean ± standard error. One Way ANOVA and Student’s t test was 
applied to all analyses with p < 0.05 being considered significant.  
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2.4. Results 
2.4.1. Decreased HNF4a Protein Expression and Transcriptional Activity During Initiation of 
Regeneration After Partial Hepatectomy. 
First, we investigated the expression and activity of HNF4a in liver regeneration after PH in 
C57BL/6J mice. We measured protein expression of HNF4a adult isoforms using Western 
blotting in freshly prepared nuclear (Figure 2.4.1A, 2.4.1C) and cytoplasmic (Figure 2.4.1B) 
protein extracts. Nuclear HNF4a levels started declining at 1 (hour) hr post-PH reaching the 
lowest level at 6 hr post-PH. Nuclear HNF4a protein expression started rising at 12 hr, increased 
higher than the 0 hr levels peaking at 3 days post PH and then declined again to reach the 0 hr 
levels by 7 days post-PH (Figure 2.4.1A, 2.4.1C). Cytoplasmic HNF4a expression continually 
declined below 0 hr levels until 12h post-PH, then started to rise but did not return to 0 hr pre-PH 
levels till 14 days after PH. GAPDH and Histone H3 were used as additional loading controls 
and to determine the purity of nuclear and cytoplasmic extracts. The expression of adult isoform 
of HNF4a mRNA did not change over the entire regeneration time course (Figure 2.4.1D).  
 
We assessed HNF4a transcriptional activity by qPCR analysis of its target genes at the 0, 6 and 
12 hr time points when nuclear HNF4a protein levels were at their lowest levels. Both positive 
and negative targets of HNF4a were identified using results from previously published RNA-
Seq data (Walesky, Edwards, et al., 2013) and are also known to bind HNF4a in their promoters 
using previously published ChIP-Seq data (Hoffman et al., 2010). We observed decreased 
expression of positive target genes (Walesky, Edwards, et al., 2013) (APOA2, APOB, CES3, 
CLDN1, CYP2C37, DIO1, F12, UGT2B1) at the 6 and 12-hr time points compared to 0 hr 
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expression levels (Figure 2.4.1E). qPCR analysis showed induction of HNF4a negative target 
genes (AKR1B7, CCND1, ECT2, MYC) at the 6 and 12 hr time points (Figure 2.4.1F). Together, 
these data indicate a decrease in HNF4a activity at the onset of regeneration which is consistent 
with the changes we observed in HNF4a protein expression (Figure 2.4.1A-C).  
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Figure 2.4.1. Decreased HNF4a protein expression and transcriptional activity during 
initiation of regeneration after partial hepatectomy. Western blot analysis of HNF4a adult 
isoform in (A) nuclear and (B) cytoplasmic lysates from mouse liver over a time course of 0 – 14 
days after 2/3 PH. (C) Densitometric analysis of nuclear HNF4a blot. (D) qPCR analysis of 
HNF4a adult isoform mRNA over a time course of 0 – 14 days after 2/3 PH. Fold change 
calculated by comparison to 0 hr time point. qPCR analysis of positively regulated (E) and 
negatively regulated (F) HNF4a target genes at 0, 6 and 12 hr post-PH. Fold change calculated 
by comparison to 0 hr time point. *indicate significant difference at P £ 0.05.  
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2.4.2. Role of Src Kinase in Regulation of HNF4a Expression After PH 
Since nuclear HNF4a protein levels decreased during initiation of liver regeneration without 
changes to HNF4a mRNA expression, we hypothesized that the decrease in nuclear HNF4a was 
caused by a post-translational regulation of HNF4a protein. Src kinase has been shown to 
phosphorylate HNF4a leading to its cytoplasmic translocation and degradation (Chellappa, 
Jankova, et al., 2012). To test this hypothesis, C57BL/6J mice were treated with the Src inhibitor 
PP2 before undergoing PH. Mice were sacrificed 6 hours post-PH. This timepoint was selected 
because this is when we observed the lowest levels of nuclear HNF4a in the WT time course. 
Consistent with our hypothesis, nuclear HNF4a protein was higher in mice treated with PP2 
(Figure 2.4.2A). Cytoplasmic HNF4a was not noticeably different in PP2 treated mice compared 




Figure 2.4.2. c-SRC kinase inhibition increases nuclear HNF4a 6 hours after partial 
hepatectomy. Mice were injected with either 5 mg/kg PP2, a c-SRC kinase specific inhibitor, or 
vehicle (Veh.) daily for 4 days before undergoing partial hepatectomy and were euthanized 6 
hours later. (A) Western blot analysis of HNF4a in nuclear and cytoplasmic extracts from livers 




2.4.3. HNF4a Overexpression Delays But Does Not Prevent Hepatocyte Proliferation During 
Liver Regeneration 
We used a Tet-On-HNF4a transgenic mouse system (Das, Tenenbaum, & Berkhout, 2016) to 
overexpress HNF4a in hepatocytes to test if the anti-proliferative effects of HNF4a would 
prevent hepatocyte proliferation during the initiation of liver regeneration (Figure 2.4.3). 
Western blot analysis confirmed increased HNF4a in nuclear lysates from livers of doxycycline 
(Dox)-treated Tet-On-HNF4a mice at 6 hours post-PH (Figure 2.4.4A). This resulted in fewer 
PCNA-positive nuclei in Dox-treated mice 6 hours post-PH and increased, although statistically 
similar, levels of proliferation at 48 hours post-PH. (Figure 2.4.4B-C). Interestingly, Dox 
treatment inhibited the occurrence of transient steatosis 48 hours post-PH (Figure 2.4.4D). qPCR 
analysis of HNF4a target genes demonstrated correlation between HNF4a overexpression and 
increased HNF4a activity. Increased expression of (Figure 2.4.4E) HNF4a positive target genes 
(ALAS2, APOA2, CYP2C37, CPT1, HNF4A, UGT2B1) and decreased expression of (Figure 
2.4.4F) HNF4a negative target genes (CCND1, CDKN3, EGR1) was observed in DOX treated 
mice before and after PH.  
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Figure 2.4.3. Schematic depicting mechanism of HNF4a overexpression in Tet-On-HNF4a 
mouse. (A) In DOX free conditions, rtTA transcription factor is constitutively expressed under a 
hepatocyte specific C/EBPb promoter. (B) In the presence of DOX, rtTA transcription factor 




Figure 2.4.4. HNF4a overexpression temporarily delays initiation of liver regeneration. (A) 
Western blot analysis confirming overexpression of HNF4a in nuclear lysates from livers of 
untreated (NT) and Dox treated Tet-On-HNF4a mice 6 hrs post-PH. (B) Quantified results for 
immunohistochemical analysis of PCNA positive nuclei. Representative micrographs (40x) of 
(C) PCNA stained liver sections and (D) H&E-stained sections from untreated and Dox treated 
Tet-On-HNF4a mice at 6 and 48 hours post-PH. RT-PCR analysis of HNF4a (E) positive target 
genes and (F) negative target genes from untreated and Dox treated Tet-On- HNF4a mice at 6 
and 48 hours post-PH. * indicate significant difference at P £ 0.05. 
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2.4.4. Hepatocyte-Specific HNF4a-KO Mice Do Not Survive After PH. 
Next, we investigated the effect of hepatocyte-specific HNF4a deletion on liver regeneration 
after PH. WT and HNF4a-KO mice underwent PH and were euthanized at 1, 2, 5, 7 and 14 days 
after surgery. HNF4a protein remained undetectable in HNF4a-KO mice throughout the time 
course after PH (Figure 2.4.5A). We observed 100% mortality in the HNF4a-KO group by day 
11 post-PH (Figure 2.4.5B). Interestingly, while liver to body weight ratios were significantly 
higher in HNF4a-KO mice before PH, the recovery of liver weight was similar between WT and 
HNF4a-KO groups until 5 days post PH (Figure 2.4.5C). Serum bilirubin was significantly 
elevated in HNF4a-KO mice at days 1, 2 and 5 post-PH (Figure 2.4.5D). While serum bilirubin 
in HNF4a-KO animals did decrease over time, this assay could only be performed on surviving 
mice and most HNF4a-KO mice died before bilirubin could be measured at later time points. 
Serum bilirubin values were significantly higher in HNF4a-KO mice when summarized as the 




Figure 2.4.5. Complete mortality of HNF4a-KO mice following PH. (A) Western blot of 
HNF4a confirming efficient KO of HNF4a in pooled liver lysates at all time points post-PH. (B) 
Kaplan-Meier survival analysis of WT and HNF4a-KO groups after PH. (C) Liver weight to 
body weight ratios and (D) serum bilirubin levels in WT and HNF4a-KO mice after PH for each 
time point after PH. Inset represents the area under the curve (AUC) values for bilirubin 




2.4.5. Sustained Loss of HNF4a Transcriptional Activity In HNF4a-KO Mice 7 Days Post-PH. 
We investigated changes in HNF4a target gene expression in WT and HNF4a-KO mice at 7 
days after PH, which revealed a significant decrease in expression of positive target genes 
including ALAS2, APOA2, APOB, CLDN1, CYP2C37, DIO1, F12 and UGT2B1 (Figure 2.4.6A). 
Similarly, the expression of the negative targets AKR1B7, CCND1, CDKN3, DEFB1, ECT2, 




Figure 2.4.6. Sustained Loss of HNF4a Transcriptional Activity In HNF4a-KO Mice 7 
Days Post-PH. qPCR analysis of mRNA isolated from frozen liver in WT and HNF4a-KO mice 
7 days post-PH. (A) Decreased expression of positive targets of HNF4a and (B) increased 
expression of negative targets of HNF4a. *indicate significant difference at P £ 0.05 between 
WT and HNF4a-KO. 
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2.4.6. Increased Hepatocyte Proliferation in HNF4a-KO Livers Throughout Regeneration. 
Western blot analysis indicated that protein expression of Cyclin D1, the cyclin involved in 
driving G0 to G1 and G1 to S cell cycle transition, was significantly increased in HNF4a-KO 
livers at all time points. The expression of CDK4, the cyclin dependent kinase interacting with 
Cyclin D1 was lower in HNF4a-KO liver at days 1 and 2 post PH but increased to levels 
comparable to WT mice by days 5 post PH. Cell proliferation assessed by Western blot and 
immunohistochemical analysis of PCNA revealed an elevated PCNA level in HNF4a-KO mice 
at all time points (Figure 2.4.7A). Immunohistochemical analysis of PCNA-positive nuclei per 
40x field was significantly higher in HNF4a-KO mice throughput the 7-day time course post PH 




Figure 2.4.7. Increased hepatocyte proliferation in HNF4a-KO livers throughout 
regeneration. (A) Western blot analysis of Cyclin D1, CDK4, and PCNA over a time course of 
0 to 7 days post-PH. (B) Quantification of immunohistochemical analysis for PCNA positive 
nuclei in liver sections of WT and HNF4a-KO mice throughout time course post-PH. Means for 
each group indicated in black and values from individual mice indicated in gray. (C) 
Representative photomicrographs (400x) of PCNA-stained liver sections from WT and HNF4a-
KO mice throughout time course post-PH. *indicate significant difference at P £ 0.05 between 




2.4.7. Activation of Pro-Proliferative Signaling in HNF4a-KO Mice During Regeneration 
We investigated the mechanism of sustained hepatocyte proliferation throughout regeneration in 
HNF4a-KO mice by Western blot analysis of pathways commonly involved in hepatocyte 
proliferation. We focused on pathways downstream of primary hepatocyte mitogen signaling as 
well as those known to activate hepatocyte proliferation in the absence of HNF4a (Paranjpe et 
al., 2016; Walesky, Edwards, et al., 2013). Most interestingly, we observed complete loss of total 
EGFR and total c-MET protein expression in HNF4a-KO animals at all time points throughout 
regeneration (Figure 2.4.8A). Interestingly, it has been shown that signaling through these 
receptors is required for proliferation to occur after PH (Paranjpe et al., 2016). Next, we 
examined Wnt/b-catenin pathway members (Figure 2.4.8B). Total b-catenin levels were similar 
in WT and HNF4a-KO mice before PH and did not change throughout the time course. 
However, inactive (Thr41/Ser45- phosphorylated) b-catenin was elevated in the WT animals at 
days 1 and 2 post-PH. Phosphorylated b-catenin was greater in HNF4a-KO compared to WT 
mice 5 days post-PH. Densitometric analysis of inactive to total b-catenin ratio suggested 
activation of b-catenin was higher in HNF4a-KO mice at 1 and 2 days post-PH (Figure 2.4.8C). 
Total GSK-3b levels did not change for both groups throughout the time course. Inactive (ser9-
phospho) GSK-3b was higher in both groups at days 1 and 5 post-PH, but no difference was 
observed between groups. Next, we investigated activation of several MAPK members including 
AKT, p38 and ERK1/2 (Figure 2.4.8D). No difference in total AKT and total p38 protein levels 
was observed between groups throughout regeneration. Phosphorylation of AKT was inhibited in 
the HNF4a-KO mice as compared to WT at days 0, 1 and 5 post-PH but was similar to WT at 
day 2 after PH. Phosphorylation (activation) of p38 was elevated in HNF4a-KO mice at days 1 
and 5 post-PH. Finally, Total ERK1/2 expression was elevated in HNF4a-KO animals at all time 
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points. Phosphorylation (activation) of ERK1 (upper band) was increased in HNF4a-KO animals 
compared to WT at all time points. Phosphorylation (activation) of ERK2 (lower band) was 
inhibited in HNF4a-KO group compared to WT at days 0 and 5 post-PH. ERK2 phosphorylation 
was elevated in HNF4a-KO group compared to WT at day 7 post-PH. Finally, we measured 
mRNA expression of known regulator of hepatocyte proliferation and negative target of HNF4a 
c-MYC which was elevated throughout regeneration (Figure 2.4.8E). While c-MYC protein 
expression was similar between WT and HNF4a-KO animals at day 0, c-MYC expression was 




Figure 2.4.8. Activation of pro-proliferative signaling in HNF4a-KO mice during 
regeneration. Western blot analysis of (A) total EGFR and c-Met, (B) total and phosphorylated 
b-catenin and total and phosphorylatedGSK3b, (C) line graphs showing densitometric signal of 
inactive to total b-catenin, (D) Western blots for Total AKT, Phospho-AKT, Total p38, Phospho-
p38, ERK1/2, Phospho-ERK1/2,  (E) qPCR analysis of c-Myc mRNA from WT and HNF4a-KO 
livers over time course post-PH, (F) Western blot analysis of c-Myc, (G) and densitometric 
analysis of c-Myc. *indicate significant difference at P £ 0.05between WT and HNF4a-KO. 
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2.4.8. RNAseq Revealed Sustained Increase in Pro-Proliferative and Anti-Differentiation 
Signaling in HNF4a-KO Mice Post-PH  
To gain insights in the comprehensive signaling changes in HNF4a-KO livers after PH, we 
performed RNA-Seq analysis at days 2 and 5 post-PH. These time points were selected to match 
the peak hepatocyte proliferation (day 2 post PH) and early termination phase of regeneration 
(day 5 post PH) in the liver regeneration process. Overall, a similar number of genes (~1,000) 
increased and decreased at day 2 and day 5 after PH in HNF4a-KO mice as compared to WT 




Table 2.4.1: Total Number of Gene Expression Changes Occuring in HNF4α-KO Mice 
Compared to WT Mice At 2 and 5 Days Post-PH. 
Number of Gene Expression Changes in HNF4a-KO Mice Post-PH 
  Day 2 Day 5 
Upregulated 880 1040 




Ingenuity Pathway Analysis (IPA) predicted activation and inhibition of transcription factors 
based on gene expression changes between genotypes. At 2 days post-PH (Table 2.4.2), IPA 
predicted activation of effectors of proinflammatory signaling (EGR1, IRF3, IRF6, IRF7) and 
proproliferative transcription factors (JUN, RB1, P300, TCF3) in HNF4a-KO liver. 
Interestingly, HNF4a-KO also showed activation of TGF-b signaling as indicated by activation 
of SMAD2 and SMAD4 as well as inhibition of SMAD7 (Fabregat et al., 2016). The 
transcription factors predicted to be inhibited 2 days post-PH included HNF4a, HNF1A and the 
HNF4a coactivator PPARGC1A (PGC1A). Furthermore, Estrogen Receptor a (Esrra), which is 
known to regulate gene expression in coordination with HNF4a and PGC1A (Charos et al., 
2012), was also predicted to be inhibited. TAF4, a known HNF4a cofactor which is required for 
HNF4a transcriptional activity (Alpern et al., 2014), was also inhibited. MED1, which is 
essential for PPARa activity and required for survival after PH (Jia, Viswakarma, & Reddy, 
2014), was inhibited in HNF4a-KO 2 days post-PH. ZBTB20, a known suppressor of hepatocyte 
proliferation and repressor of alpha-fetoprotein (Weng et al., 2014; Xie et al., 2008), was 
predicted to be inhibited.  
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Table 2.4.2: Predicted Activity of Transcription Factors in HNF4 -KO Mice Compared to 
WT Mice 2 Days Post-PH 
Day 2 Post-PH 
Activated Pathways Activation z-score Inhibited Pathways Activation z-score 
JUN 3.31 HNF4A -6.498 
EGR1 2.814 HNF1A -4.428 
RB1 2.497 Esrra -3.357 
IRF3 2.42 PPARGC1A -3.228 
FOXO4 2.377 NFIX -2.433 
EP300 2.305 ZBTB20 -2.294 
SPI1 2.248 MED1 -2.272 
THRAP3 2.219 CLOCK -2.219 
IRF6 2.215 NFIC -2.2 
SMAD4 2.201 GATA2 -2.059 
MTA1 2.194 NKX2-3 -2.04 
Gm21596/Hmgb1 2.169 E2F1 -2.027 
IRF7 2.163 SMAD7 -2.027 
SMAD2 2.068 TAF4 -2.008 




At day 5 post-PH (Table 2.4.3), the analysis predicted activation of transcription factor 
proinflammatory damage associated molecular pattern (DAMP) protein HMGB1 in HNF4a-KO 
mice indicating sustained inflammatory signaling in HNF4a-KO mice throughout regeneration. 
The TGFb effector SMAD2 was also activated at day 5 post-PH. Proliferative marker EP300 
was activated at day 5 post-PH. The HNF4a negative target gene and proliferative marker 
CCND1 was activated in the HNF4a-KO group at day 5 post-PH indicated sustained 
proliferative signaling compared to WT mice. Activation of SNAI2 was predicted in the HNF4a-
KO group at 5 days post-PH. SNAI2 is repressed by HNF4a and is known to promote EMT 
(Santangelo et al., 2011). PLAG1 is a fetal gene overexpressed in hepatoblastomas (Juma, 
Damdimopoulou, Grommen, Van de Ven, & De Groef, 2016) and was predicted to be activated 
in the HNF4a-KO group at day 5. Activation of TRIM24, a transcription factor with oncogenic 
activity (Appikonda, Thakkar, & Barton, 2016), was predicted at day 5 post PH in the HNF4a-
KO mice. Transcription factors including HNF4A, HNF1A, PPARGC1A, and Esrra were 
inhibited at day 2 post-PH and continued to be inhibited at day 5 post-PH. Inhibition of SIRT2 
was observed at 5 days post-PH in HNF4a-KO mice consistent with its known role in sharing 
many of the same target genes as HNF4a(Palu & Thummel, 2016). PPARGC1B is a known 
coactivator of PPARGC1A and was inhibited. NCOA2 and EBF1, known tumor 
suppressors(Armartmuntree et al., 2018; O'Donnell et al., 2012), were inhibited in HNF4a-KO 
mice day 5 post-PH. NFIX, a transcription factor known to inhibit development of HCC(Hu et 
al., 2018), was inhibited. Finally, the master regulators of sterol and lipid metabolism, SREBF1 
and SREBF2, were inhibited 5 days post-PH. 
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Table 2.4.3: Predicted Activity of Transcription Factors in HNF4a-KO Mice Compared to 
WT Mice 5 Days Post-PH. 
Day 5 Post-PH 
Activated Pathways Activation z-score Inhibited Pathways Activation z-score 
Gm21596/Hmgb1 2.767 HNF4A -6.471 
EP300 2.565 HNF1A -4.641 
TRIM24 2.554 SREBF2 -4.603 
SMAD2 2.401 SREBF1 -3.768 
CCND1 2.307 PPARGC1A -3.045 
SNAI2 2.1 Esrra -2.887 
ANKRD42 2 IRF7 -2.476 




















IPA analysis also predicted activity of diseases and organ function based on gene expression 
differences between WT and HNF4a-KO mice at 2 and 5 days post-PH. The comparison at day 
2 post-PH (Table 2.4.4) predicted HNF4a-KO mice would exhibit activation of pathways 
involving inflammation, tumorigenesis and wound healing. Inhibited functions included 
numerous basic liver processes such as transport, metabolism and synthesis of cholesterol, lipids, 
bile acids and xenobiotics.  
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Table 2.4.4: Predicted Activation or Inhibition of Diseases and Functions in HNF4a-KO 
Mice Compared to WT Mice 2 Days Post-PH. 
Day 2 Post-PH 
Activated Functions Activation z-score Inhibited Functions Activation z-score 
homing of cells 2.502 metabolism of retinoid -3.653 
hematopoiesis of phagocytes 2.308 metabolism of vitamin -3.527 
energy homeostasis 2.165 metabolism of tretinoin -3.398 
myelopoiesis of leukocytes 2.095 transport of lipid -3.371 
chemotaxis 2.073 metabolism of xenobiotic -3.073 
liver lesion 2.065 flux of lipid -3.006 
tumorigenesis of tissue 2.015 transport of steroid -2.997 
  
 
flux of cholesterol -2.974 
  
 
fatty acid metabolism -2.925 
  
 
efflux of cholesterol -2.843 
  
 
efflux of lipid -2.77 
  
 
uptake of lipid -2.753 
  
 
metabolism of terpenoid -2.683 
  
 
transport of cholesterol -2.68 
  
 
synthesis of terpenoid -2.632 
  
 
uptake of bile salt -2.578 
  
 
esterification of cholesterol -2.551 
  
 
export of molecule -2.537 
  
 
production of retinoid -2.396 
  
 
hydroxylation of lipid -2.241 
  
 
transport of rosuvastatin -2.236 
  
 
uptake of fexofenadine -2.219 
  
 
tonic-clonic seizure -2.219 
  
 
synthesis of lipid -2.139 
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This pattern continued at day 5 post-PH (Table 2.4.5). Activated functions continued to be 
related to cell proliferation, tumorigenesis and inflammation. Additionally, functions related to 
embryonic organ tissue development were activated in the HNF4a-KO group. Functions related 
to transport and metabolism of lipids, cholesterol and vitamins remained inhibited in HNF4a-KO 
mice 5 days post-PH. 
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Table 2.4.5: Predicted Activation or Inhibition of Diseases and Functions in HNF4a-KO 
Mice Compared to WT Mice 5 Days Post-PH. 
Day 5 Post-PH 
Activated Functions 
Activation z-
score Inhibited Functions 
Activation z-
score 
sepsis 2.95 uptake of lipid -3.472 
stimulation of cells 2.891 metabolism of vitamin -3.031 
proliferation of cancer cells 2.783 metabolism of retinoid -2.832 
development of genitourinary system 2.698 
metabolism of 
xenobiotic -2.559 
proliferation of tumor cells 2.574 
metabolism of amino 
acids -2.449 
tumorigenesis of tissue 2.555 fatty acid metabolism -2.38 
immediate hypersensitivity 2.547 weight gain -2.344 
development of urinary tract 2.541 transport of lipid -2.212 
inflammation of absolute anatomical 
region 2.494 flux of lipid -2.204 
neoplasia of epithelial tissue 2.414 secretion of hormone -2.107 
assembly of cells 2.409 flux of cholesterol -2.055 
growth of malignant tumor 2.383     
development of body trunk 2.373     
inflammation of liver 2.3     
endothelial cell development 2.289     
inflammation of organ 2.253     
acute phase reaction 2.219     
development of epithelial tissue 2.184     
development of abdomen 2.17     
abnormality of lower limb 2.157     
inflammation of body cavity 2.14     
formation of mammary gland 2.043     
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formation of gland 2.043     
development of exocrine gland 2.017     
activation of epithelial cells 2.008     




2.4.9. Reexpression of HNF4a Restores Hepatocyte Quiescence and Gene Expression and 
Extends Survival of HNF4a-KO Animals Post-PH 
Next we tested if reexpression of HNF4a in hepatocytes by intravenous injection of AAV8-
CMV-HNF4a could rescue HNF4a-KO mice after PH by restoring HNF4a transcriptional 
activity after cell division. First we reexpressed HNF4a in HNF4a-KO mice and measured 
HNF4a target gene expression. HNF4a reexpression increased total c-MET and total EGFR 
protein expression to WT levels and reduced cyclin D1 expression to WT levels (Figure 2.4.9A). 
Hepatocyte proliferation was assessed by immunohistochemical analysis of PCNA positive 
nuclei. High levels of hepatocyte proliferation were observed in the HNF4a-KO group. HNF4a 
reexpression resulted in decreased hepatocyte proliferation compared to HNF4a-KO mice 
(Figure 2.4.9B-C). Finally, we reexpressed HNF4a in HNF4a-KO mice 2 days post-PH. This 




Figure 2.4.9. Reexpression of HNF4a restores hepatocyte quiescence and gene expression 
and extends survival of HNF4a-KO animals post-PH. (A) Western blot analysis of HNF4a, 
Cyclin D1, c-Met and EGFR in WT, HNF4a-KO and HNF4a-Reexp. mice,  (B) 
Immunohistochemical analysis of PCNA positive nuclei in liver sections from WT, HNF4a-KO 
and HNF4a-Reexp. mice, (C) Representative photomicrographs (40x) of PCNA-stained liver 
sections, (D) Kaplan-Meier survival analysis of WT and HNF4a-Reexp mice after PH. * indicate 




HNF4a is the master regulator of hepatocyte differentiation because it is required for hepatocyte 
differentiation during embryonic liver development and it maintains hepatocyte specific gene 
expression in adult hepatocytes (Gonzalez, 2008; Kyrmizi et al., 2006; Morimoto et al., 2017). 
HNF4a also exerts strong anti-proliferative effects on hepatocytes and decreased HNF4a 
expression and activity results in loss of quiescence, which can lead to HCC (W. Y. Cai et al., 
2017; Hatziapostolou et al., 2011; Walesky, Edwards, et al., 2013). Despite being recognized as 
one of the strongest anti-proliferative proteins in the liver, the role of HNF4a during liver 
regeneration is not known. We investigated the role of HNF4a in liver regeneration after PH, 
where adult hepatocytes exit the physiological quiescent state and enter the cell cycle before 
returning to the quiescent state once liver regeneration has been completed. We hypothesized 
that decreased HNF4a expression and function would occur during the initiation of regeneration 
to alleviate the antiproliferative effects of HNF4a as quiescent hepatocytes enter the cell cycle 
during the initiation of liver regeneration. Indeed, we observed decreased nuclear and 
cytoplasmic levels of HNF4a occurring within hours after surgery. This decreased protein 
expression was not due to changes in transcription of the HNF4a gene because there were no 
changes in HNF4a mRNA post-PH. Decreased periportal HNF4a staining after PH has been 
previously reported (Fukuda et al., 2016). However, HNF4a expression during liver regeneration 
has never been studied in a time course at this level of resolution until now. Posttranslational 
modifications (PTMs) of HNF4a which result in decreased nuclear localization are known (Z. 
Wang, Salih, & Burke, 2011; Yokoyama et al., 2011), and phosphorylation of HNF4a by PKC 
or Src can lead to proteasomal degradation of HNF4a (Chellappa, Jankova, et al., 2012; K. Sun 
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et al., 2007). We investigated how inhibiting one of these phosphorylation mechanisms, Src, 
would affect nuclear HNF4a expression 6 hours post-PH, when HNF4a was observed to be at its 
lowest levels in normal mice. Mice treated with a Src inhibitor exhibited higher levels of nuclear 
HNF4a compared to vehicle treated mice, providing evidence that phosphorylation of HNF4a 
by Src could be the mechanism through which HNF4a is removed from the nucleus after PH. 
Src and PKC are both activated by EGF through EGFR making this mechanism of HNF4a 
phosphorylation relevant to liver regeneration. However, little remains known about post-
translational regulation of HNF4a in the liver and future studies are needed to map the impact of 
individual PTMs on HNF4a and characterize how inhibition of Src, PKC and other kinases 
might change HNF4a activity in liver regeneration and other conditions. Decreased nuclear 
expression of HNF4a protein after PH resulted in decreased transcriptional activity as measured 
by its target genes, which play a critical role in liver physiology (Walesky, Edwards, et al., 
2013). Our observations independently reproduce a microarray study describing decreased 
HNF4a target gene expression 4 hours post-PH (Jiao et al., 2015). This highlights functional 
differences between quiescent and proliferating hepatocytes and suggests restoring HNF4a in 
hepatocytes responding to chronic injury could successfully restore hepatic function (T. 
Nishikawa et al., 2015; Yue et al., 2010). 
 
Next, we hypothesized that overexpressing HNF4a in hepatocytes at time points after PH when 
HNF4a levels were normally decreased would prevent hepatocytes from proliferating and halt or 
delay initiation of liver regeneration. Interestingly, our experiments with Tet-On driven HNF4a 
expression demonstrated significantly decreased hepatocyte proliferation 6 hours post-PH and an 
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almost statistically significant increase in proliferation 48 hours post-PH. Decreased proliferation 
6 hours post-PH was likely driven by decreased expression of proproliferative HNF4a negative 
target genes CCND1 and CDKN3. These data suggest that rapid down regulation of HNF4a 
after PH may accelerate hepatocyte cell cycle entry, but is not absolutely necessary for initiation 
of cell cycle progression after PH. It also suggests activation of compensatory proliferative 
pathways which can activate liver regeneration despite increased HNF4a expression, 
highlighting the redundant nature of pro-regeneration pathways. It is also possible that HNF4a 
overexpression resulted in delayed initiation because the mechanism responsible for HNF4a 
degradation was still active and more time was needed to degrade the overexpressed protein. 
Inhibiting the mechanism responsible for HNF4a degradation, such as Src kinase, might be a 
better strategy to study the effects of increased HNF4a expression during initiation of liver 
regeneration once those mechanisms are established. One interesting observation from the 
HNF4a overexpression study was the lack of steatosis in HNF4a overexpressing mice, which is 
known to occur after PH (Shteyer, Liao, Muglia, Hruz, & Rudnick, 2004). This might be caused 
by increased expression of apolipoproteins such as APOA2 which are well established HNF4a 
target genes. These data indicate that the initial loss of HNF4a could be mechanistically 
involved in the transient steatosis observed following PH and those mechanisms may be 
independent of initiation of cell proliferation. 
 
The most striking observation from our studies is 100% mortality in HNF4a-KO mice following 
PH within 11 days secondary to loss of hepatic function. HNF4a is required for ureagenesis and 
liver-specific HNF4a-KO mice have increased serum ammonia and decreased serum urea (Y. 
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Inoue et al., 2002). Several HNF4a-KO mice exhibited loss of righting reflex prior to death, a 
symptom of hepatic encephalopathy (data not shown). Decreased hepatic function further 
manifested as elevated bilirubin levels in HNF4a-KO mice after PH and a significant deficiency 
of hepatocyte differentiation gene expression at 7 days post PH in HNF4a-KO mice as compared 
to the WT mice. In contrast, a significant increase in nuclear HNF4a expression was observed in 
the control mice (Figure 2.4.1) at days 3 and 5 after PH, the time points when the cell 
proliferation decreases and redifferentiation starts. The fact that HNF4a-KO hepatocytes were 
not able to compensate for loss of HNF4a function (as measured by target gene expression) 
further supports the role of HNF4a as a master regulator of hepatic differentiation. Taken 
together, these data clearly demonstrate that HNF4a-mediated differentiation of the newly 
divided hepatocytes is an essential part of the termination of regeneration and failure to 
redifferentiate can lead to cell and animal mortality. 
 
Another important observation in our studies was the complete loss of c-MET and EGFR 
expression in HNF4a-KO mice which could contribute to the death observed in HNF4a-KO 
mice after PH. Recent studies have shown that c-MET deletion combined with EGFR inhibition 
results in death of mice without any disturbance to the liver (Tsagianni et al., 2018). These mice 
exhibited decreased serum albumin, decreased blood glucose and poor expression of hepatic 
genes involved in urea synthesis, lipid metabolism and carbohydrate metabolism. Microarray 
analysis of these mice found HNF4a to be the top prediction in a list of inhibited transcription 
factors. This study shows that baseline signaling through c-MET and EGFR is required for 
hepatocyte function in the quiescent liver and combined with our data is evidence of a positive 
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regulation feedback loop between EGFR, c-MET and HNF4a in normal liver. A combined loss 
of EGFR, c-MET and HNF4a observed in the HNF4a-KO mice could have resulted in loss of 
several redundant survival mechanisms at once, leading to death after PH. 
 
It is known that signaling induced by primary hepatic mitogens HGF and EGF family members 
(EGF, TGFa etc.) via their cognate receptors c-MET and EGFR is essential for liver 
regeneration after PH (Paranjpe et al., 2016). Mice with deletion of c-MET and inhibition of 
EGFR do not exhibit any hepatocyte proliferation after PH (Paranjpe et al., 2016). However, 
HNF4a-KO mice seem to be an exception to this rule. Despite the loss of c-MET and EGFR 
expression in HNF4a-KO mice, hepatocyte proliferation occurred at high levels before PH and a 
surge of proliferation was observed at the same time as peak proliferation in WT mice before 
returning to baseline levels, although remaining higher than WT levels. Two important 
conclusions can be made from this observation. First, increased proliferation in HNF4a-KO 
mice before and after PH is consistent with our previous findings that HNF4a is anti-
proliferative in hepatocytes (Walesky, Gunewardena, et al., 2013). Second, although 
proliferation is higher in HNF4a-KO mice before PH, the surge of additional proliferation that 
occurs in response to PH in the HNF4a-KO mice suggests some pro-proliferative pathways 
involved in regeneration remain intact in HNF4a-KO mice. Furthermore, the occurrence of a 
regenerative response in HNF4a-KO mice, which do not express EGFR or c-MET, is the 
product of activation of a pro-proliferative pathway that is normally repressed by HNF4a. To 
address the alternate mechanisms at play, we investigated several known pathways including 
Wnt/b-catenin pathway and MAPK signaling. Whereas, significantly higher b-catenin signaling 
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was observed in HNF4a-KO mice as evident by decrease in phosphorylated (inactive) b-catenin, 
this was observed only during the early time points. Similarly, the AKT, p38 and ERK-1/2 
pathways also revealed only moderate differences between WT and HNF4a-KO mice after PH, 
which cannot explain the sustained proliferation of hepatocytes in HNF4a-KO mice. However, 
we observed a significant activation of c-Myc in HNF4a-KO mice consistent with previous 
studies showing activation of c-Myc in the absence of HNF4a (Walesky, Edwards, et al., 2013). 
Also, the role of c-Myc in liver regeneration and cancer is well documented. Our studies show 
that HNF4a-KO hepatocytes lose two of the primary mitogenic pathways, namely c-MET and 
EGFR, but proliferation continues mainly via c-Myc activation. 
 
It is well known that deletion of hepatic HNF4a increases liver to body weight ratios, which 
consistent with our observations in HNF4a-KO mice before PH (Bonzo et al., 2012; Hayhurst et 
al., 2001). However, despite exhibiting increased hepatocyte proliferation throughout the time 
after PH, there were no differences in recovery of liver weight between WT and HNF4a-KO 
mice. Liver mass is a product of cell number and cell size. Increased proliferation would 
contribute to increased cell number, but restoration of cell size after PH involves the nutrient, 
protein and water content of hepatocytes to return to normal levels. Considering the importance 
of HNF4a activity in hepatocyte function, it is likely that the processes required to restore cell 
size would take a longer time in HNF4a-KO mice, but HNF4a-KO mice die before this can be 
achieved. Thus we cannot determine if regeneration in HNF4a-KO mice would overshoot target 
liver mass due to excess proliferation. 
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The RNAseq analysis further revealed mechanisms that drive continued proliferation and also 
the mechanisms that lead to liver failure and death of the HNF4a-KO mice after PH. We 
investigated days 2 post-PH, the time points with peak proliferation, and 5 days post-PH the time 
point when termination of regeneration begins.  At both time points, the HNF4a-KO livers 
exhibited a proinflammatory and profibrotic transcriptional profile. Elevated inflammation in 
HNF4a-KO mice was not caused by hepatocellular injury, as there was no difference in ALT 
levels or histopathological changes between groups (data not shown). However, previous studies 
have reported elevated bile acid levels in HNF4a-KO livers, which could cause increased 
inflammatory signaling (Hayhurst et al., 2001). Furthermore, many HNF4a negative target genes 
such as EGR1 are pro-inflammatory. IPA analysis also supported our findings of 
dedifferentiation and loss of hepatocyte function in HNF4a-KO mice. IPA predicted consistent 
inhibition of several prominent hepatocyte functions in HNF4a-KO at day 2 and day 5 post-PH. 
However, we observed a shift in the characteristics of activated functions between the two time 
points. Most of the activated functions in HNF4a-KO mice at day 2 included those involved in 
inflammation. However, the activated functions in HNF4a-KO mice at day 5 included many 
more functions involved in proliferation, tumorigenesis and a developmentally immature 
phenotype in addition to inflammation. Furthermore, HNF4a-KO mice at day 5 were predicted 
to express higher levels of known oncogenes (TRIM24, SNAI2, PLAG1) which were not 
activated at day 2. This transformation from an abnormal regenerative response to the beginnings 
of a pathological condition raise the question of how hepatocytes with poor expression of 
HNF4a may respond to chronic or intermittent low level liver injury. The decreased expression 
of HNF4a expressed in many liver diseases and HCC may be an example of the innate 
regenerative capability of the liver contributing to the progression of liver disease.  
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We observed that reexpression of HNF4a in HNF4a-KO mice using the AAV8 resulted in 
restoration of quiescence and the expression of c-MET and EGFR. However, when the HNF4a 
construct was introduced after PH, we did not observe complete prevention of death. This may 
be due to the timing of HNF4a reexpression (two days after PH may be too early), the possibility 
that dividing cells may have decreased sensitivity to AAV8 and that the dividing cells may reject 
AAV8-mediated introduction of exogenous material. Nevertheless, following HNF4a 
reintroduction into HNF4a-KO mice after PH did significantly increase survival time compared 
to HNF4a-KO counterparts included in this experiment and those used in the deletion time 
course. Even if HNF4a reexpression was not 100% efficient in dividing hepatocytes, delayed 
mortality due to partial restoration of hepatic function through HNF4a expression supports 
hepatic failure being the cause of death in these animals. 
 
In summary, our studies are the first to examine and manipulate HNF4a expression over 
multiple time points throughout the initiation, progression and termination of liver regeneration 
after partial hepatectomy. Our findings suggest downregulation of HNF4a may contribute to 
hepatocyte cell cycle entry during initiation of regeneration. More importantly, reestablishment 
of HNF4a activity during termination of regeneration is absolutely required for termination of 
regeneration and resumption of hepatocyte function. This study uncovers new evidence of 
HNF4a mediated expression of EGFR and c-MET and demonstrate that HNF4a-KO mice are 
capable of mounting a regenerative response despite lacking these receptors. Furthermore, 
regeneration in the absence of HNF4a results in a dedifferentiated, pro-carcinogenic hepatocyte 
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phenotype. These results confirm the role of HNF4a as a major player in hepatocyte 
proliferation and differentiation during liver regeneration.  
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Chapter 3. Using HNF4a Gene Signature to Determine Hepatocellular 




Hepatocellular carcinoma (HCC) is the major hepatic malignancy and third leading cause of 
cancer related deaths in the world with extremely limited treatment options. An important issue 
is lack of tools to determine the disease progression from the non-malignant stages such as liver 
cirrhosis to cancer and further progression of disease from early stage cancer to later stage HCC 
are limited. Recent studies have identified role of Hepatocyte Nuclear Factor 4a (HNF4a) in 
inhibition of hepatocyte proliferation and HCC pathogenesis. Here we report that HNF4a 
activity as measured by using a specific HNF4a target gene signature can be used as an excellent 
predictive tool in HCC disease progression. We identified a specific HNF4a gene expression 
signature using RNAseq-ChIPseq data obtained from hepatocyte specific HNF4a knockout 
(HNF4aKO) mice, which was further refined for use in human samples. Validation studies were 
performed using HNF4aKO mice and diethylnitrosamine-initiated cholic acid promoted mouse 
HCCs. We initially performed an in silico analysis using three independent gene expression data 
sets consisting of a total of 102 individual human samples. Cluster analysis performed using 
HNF4α gene signature was successful in distinguishing Cirrhotic-non-HCC from cirrhotic-with 
HCC with >80% specificity; differentiate between normal, cirrhotic non-HCC, dysplastic 
nodules, early stage HCC and advanced HCC with >85% specificity and distinguish HCC from 
paired non-tumor tissues with 100% specificity. Further studies with two independent sets of 
human samples (n=26 total) of various stages of HCC disease progression corroborated the in 
silico analysis. Finally, survival analysis performed on a total of 365 HCC samples indicated that 
the HNF4a target gene signature was able to clearly distinguish cases with shorter survival, 
which had significantly lower HNF4a activity. These data indicate that loss of HNF4α is a 
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critical factor in HCC and HNF4α function as measured by target gene expression is a potential 
predictive biomarker in HCC pathogenesis in humans.  
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3.2. Introduction 
The role of HNF4a in hepatocyte differentiation and proliferation, along with its activity in liver 
disease is detailed in Chapter 1. In the liver, hepatocyte-specific deletion of HNF4a results in 
hepatomegaly, spontaneous hepatocyte proliferation and promotion of DEN-induced liver 
cancers (Bonzo et al., 2012; Walesky, Edwards, et al., 2013; Walesky, Gunewardena, et al., 
2013). Globally, there are 850,000 new cases of Hepatocellular Carcinoma (HCC) every year 
(Torre et al., 2015) and it is the second leading cause of cancer related deaths worldwide 
("Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 
causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013," 
2015). Disease prevalence and limited treatment options made HCC the leading indication 
among liver transplant registrants and recipients in 2015 (J. D. Yang et al., 2017). It is known 
that 3-5% of cirrhotic patients will develop HCC each year (Villanueva et al., 2010) and HCC is 
a leading cause of death among cirrhotic patients (Sangiovanni et al., 2004). Overwhelming 
demand on organ donation networks as well as decreased quality of donor livers has resulted in a 
shortage of available livers (Habka, Mann, Landes, & Soto-Gutierrez, 2015). When following 
the BCLC staging and treatment schedule, early detection and accurate prognosis is critical for 
curative treatment of HCC (Josep M. Llovet, Burroughs, & Bruix, 2003). This can be 
accomplished by screening patients likely to develop HCC, such as those with cirrhosis, or by 
the molecular classification of diagnosed HCCs (Bruix, Han, Gores, Llovet, & Mazzaferro, 
2015). Predicting which cirrhotic patients will develop HCC would lead to improved outcomes 
and decreased consumption of donor liver supply.  
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The prevalence of data linking decreased HNF4a expression with progression of liver cancer led 
us to hypothesize that the development and advancement of HCC occurs with a corresponding 
decrease in HNF4a expression and activity. Here, we report the identification of an HNF4a 
target gene signature and demonstrate its ability to measure HNF4a activity in human and mouse 
liver tissue and gene expression datasets. This signature revealed a pattern of decreased HNF4a 
activity that correlated with progression of HCC. Our results demonstrate the potential of this 
gene signature to refine current screening protocols and prognostic algorithms in the treatment of 
HCC.  
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3.3. Materials and Methods 
3.3.1. Animals and Generation of Global Gene Expression Datasets 
The generation of hepatocyte specific conditional HNF4a-KO mice and induction of HCCs in 
the HNF4a-KO mice has been previously published (Walesky, Edwards, et al., 2013). Two 
RNAseq datasets were generated. First, differentially expressed genes (DEGs) in the livers of 
WT and HNF4a-KO mice were identified using RNAseq as previously published (Walesky, 
Edwards, et al., 2013). The second RNAseq dataset was generated using HCCs isolated from WT 
and HNF4a-KO mice (three tumors per genotype) as described before (Walesky, Edwards, et al., 
2013). Additionally, a published HNF4a chromatin immunoprecipitation sequencing dataset 
(ChIPseq) for mouse liver was used for the analysis (Hoffman et al., 2010). These three datasets 
were used to determine the HNF4a target gene signature.  
 
3.3.2. Identification of HNF4a Target Gene Signature 
The strategy used to identify genes included in the HNF4a target gene signature is illustrated in 
Figure 3.4.1A. First, RNA-Seq analysis of normal liver tissue from WT and hepatocyte-specific 
HNF4a mice identified 829 genes with a minimum 2-fold difference in expression between 
groups (Dataset 1). This dataset selected for genes that are directly and indirectly regulated by 
HNF4a. Next, RNA-Seq analysis performed on liver tumor tissue from WT and hepatocyte-
specific HNF4a-KO mice identified 2152 genes with a minimum 2-fold difference in expression 
between groups (Dataset 2). The genes from Dataset 1 and Dataset 2 were compared to Dataset 3 
which contained genes identified in a previously published HNF4a ChIP-Seq dataset (Hoffman 
et al., 2010). This identified genes that were directly regulated by HNF4a by selecting for genes 
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with a HNF4a binding site within 5kb of the transcription start site and was termed  Dataset 4, 
which contains 323 genes were found in common between Dataset 1-3. Further, to reduce the 
number of genes in the signature such that analysis of signature expression can be conducted 
using a 96-well Taqman-based qPCR approach and to account for differences between human 
and mouse gene expression, Dataset 4 was refined using IPA analysis to identify genes. The 
resulting 44 genes contained in Dataset 5 identified the HNF4a Target Gene Signature.  
3.3.3. Confirmation of HNF4a Target Gene Signature 
For confirmation of target gene signature, total hepatic mRNA from WT and HNF4a-KO mice 
were used as described before (Walesky, Gunewardena, et al., 2013). For further analysis of the 
gene signature, used mRNA samples generated in a recently published HCC study in our 
laboratory where we had investigated the role of bile acids in promoting DEN-induced liver 
cancer (L. Sun et al., 2016). The experimental design included four groups including Controls 
(DEN- CA-), 0.2% cholic acid alone (DEN- CA+), DEN alone no cholic acid (DEN+ CA-) and 
DEN+ cholic acid (DEN+ CA+).  The treatment protocols, tissue collection methods, and results 
from this study have been previously published (L. Sun et al., 2016). 
 
3.3.4. Human Samples 
All human liver, RNA, and paraffin embedded sections were obtained from the University of 
Kansas Medical Center Liver Tissue Bank. Samples were obtained with informed consent from 
patients in accordance with ethical and institutional guidelines. The Institutional Review Board 
at the University of Kansas Medical Center approved this study. 
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3.3.5. qPCR 
Total RNA was harvested from frozen livers using the TRIzol method according to 
manufacturer’s protocol (Life Technologies, Carlsbad, CA). Quality and quantity of isolated 
RNA was determined using a NanoDrop 1000 Spectrophotometer (ThermoScientific). RNA was 
converted to cDNA as previously described (Apte et al., 2009). Expression of HNF4a transcripts 
in human samples were determined using an Applied Biosystems StepOnePlus Real-Time PCR 
System with SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) as 
previously described (Beggs et al., 2016). Human primers were designed as follows: HNF4a, 5′-
aagccgtccagaatgagc-3′ (forward) and 5′-aatgtcgccgttgatccc-3′ (reverse), GAPDH, 5′-
tgatgacatcaagaaggtggtgaag-3′ (forward) and 5′-tccttggaggccatgtgggccat-3′ (reverse). Fold change 
in gene expression was calculated using the 2-∆∆Ct method (Livak & Schmittgen, 2001).  
 
For HNF4a gene signature analysis, Ct values of genes included in the HNF4a target gene 
signature were determined using a custom made TaqMan Gene Expression Assays containing 
species specific primers for each gene in the signature (Applied Biosystems, Foster City, CA). 
Each TaqMan array had 44 genes and 4 housekeeping internal controls in duplicates. The ∆Ct 
values of signature genes were calculated by subtracting the geometric mean of Ct values from 4 
housekeeping control genes (18S, GAPDH, HPRT, GUSB) (Vandesompele et al., 2002) from the 
Ct values of each signature gene. 
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3.3.6. Hierarchical Clustering and Heatmaps 
Expression of HNF4a signature genes was analyzed using hierarchical clustering modules from 
GenePattern (Reich et al., 2006). The HierarchicalClustering module uses algorithms originally 
published in 1998 (Eisen, Spellman, Brown, & Botstein, 1998) and later improved (de Hoon, 
Imoto, Nolan, & Miyano, 2004). Raw values used for the clustering process were -∆Ct values for 
each gene. Module settings were specified such that column and row distance was determined by 
calculating Euclidean distance measurement. The clustering method used was pairwise 
complete-linkage. Rows were mean-centered and normalized. Files generated using this module 
were used by the HierarchicalClusteringViewer module to generate heatmaps and dendrograms. 
 
3.3.7. Immunohistochemistry 
Paraffin-embedded human liver sections were stained with hematoxylin-eosin using an 
autostainer (model CV 5030, Leica Microsystems, Buffalo Grove, IL). Additional sections were 
used for immunohistochemical detection of HNF4a using a staining procedure that has 
previously been described (Wolfe et al., 2011) with a modification to the antigen retrieval step. 
Instead of boiling, slides submerged in citrate buffer were subjected to autoclave treatment. The 
primary antibody used for HNF4a detection (PP-H1415-00, Perseus Proteomics Inc., Tokyo, 
Japan) was diluted 1:500 and incubated on samples overnight at 4°C.  
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3.4. Results 
3.4.1. Validation of HNF4a Target Gene Signature 
 To test the ability of the HNF4a target gene signature (Figure 3.4.1A, Dataset 5) to detect 
HNF4a activity, we used qPCR to measure signature gene expression in WT (CRE+ CO and 
CRE- CO), tamoxifen (TAM) control (Cre- CO) and HNF4a-KO mice (CRE+ TAM). Group 
average -∆Ct values were used to generate the heatmap (Figure 3.4.1B). Expression of signature 
genes was decreased in the HNF4a-KO group compared to all control groups. The column 
dendrogram shows three WT samples, including the TAM control, clustering together away from 
the HNF4a-KO group. Fold change values for each gene when compared to the CRE+ CO group 
are found in Table 3.4.1. Gene names have been replaced with numbers due to ongoing patent 
application, which prevents us from describing them. Together, these data demonstrate the 
ability of the HNF4a target gene signature to measure HNF4a activity.  
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Table 3.4.1: Fold change values of HNF4a target signature genes as compared to CRE+ mice 
treated with corn oil. Gene expression was measured using custom made Taqman qPCR plates. 
 Gene # CRE+ TAM CRE- TAM CRE- CO CRE+ CO 
1 0.115 0.600 0.476 1 
2 0.104 0.523 0.480 1 
3 0.083 0.533 0.666 1 
4 0.151 0.620 0.796 1 
5 0.065 0.427 0.883 1 
6 0.023 0.255 0.615 1 
7 0.008 0.137 0.693 1 
8 0.150 0.586 1.278 1 
9 0.099 1.066 1.591 1 
10 0.145 0.921 1.717 1 
11 0.092 0.789 1.750 1 
12 0.448 0.587 1.038 1 
13 0.030 0.077 0.513 1 
14 0.252 0.446 0.750 1 
15 0.095 1.532 1.158 1 
16 0.164 1.546 1.218 1 
17 0.235 1.512 1.109 1 
18 0.094 1.764 0.905 1 
19 0.277 1.295 0.915 1 
20 0.037 1.334 0.731 1 
21 0.028 1.494 0.730 1 
22 0.036 1.246 0.619 1 
23 0.285 1.047 0.861 1 
24 0.022 1.130 0.641 1 
25 0.112 1.036 0.847 1 
26 0.250 1.050 0.940 1 
27 0.040 1.290 0.909 1 
28 0.036 1.452 1.063 1 
29 0.084 0.793 0.634 1 
30 0.130 0.958 0.739 1 
31 0.246 0.938 0.765 1 
32 0.023 1.060 1.044 1 
33 0.076 0.948 1.003 1 
34 0.098 0.998 1.038 1 
35 0.034 0.737 0.831 1 
36 0.056 1.820 0.538 1 
37 0.120 2.104 0.980 1 
38 0.117 2.312 1.009 1 
39 0.212 2.124 0.959 1 
40 0.238 1.698 0.877 1 
41 0.146 1.065 0.319 1 
42 0.265 8.375 1.522 1 
43 2.838 0.639 2.174 1 




Figure 3.4.1. Identification and Validation of HNF4a Target Gene Signature. (A) Schematic 
representing method used to identify 44 target genes included in the signature. Quantity of genes 
included in each dataset are indicated in parentheses. (B) Heatmap comparing expression of 
signature genes from HNF4a-KO mice (CRE+ TAM) to WT control mice (CRE- CO, CRE+ 
CO, CRE- TAM). 
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3.4.2. HNF4a Target Gene Signature Analysis in Cholic Acid-Promoted HCC 
We hypothesized that progression of HCC to more advanced forms would correlate with a 
decrease in HNF4a activity. To test this, we used mRNA samples generated in a recently 
published HCC study in our laboratory (L. Sun et al., 2016) where we had investigated the role 
of bile acids in promoting DEN-induced liver cancer. The experimental design included four 
groups: Controls (DEN- CA-), 0.2% cholic acid alone (DEN- CA+), DEN alone no cholic acid 
(DEN+ CA-) and DEN+ cholic acid (DEN+ CA+).  Out of the four groups, only DEN alone 
(DEN+ CA-) and DEN+Cholic acid (DEN+ CA+) mice had shown liver tumors. The DEN+ 
CA+ group had much higher number of tumors, which were advanced HCCs. Control groups 
(DEN- CA+, and DEN- CA-) had normal liver histology and did not develop HCC (L. Sun et al., 
2016). qPCR analysis of HNF4a signature gene expression showed high levels of HNF4a 
activity in DEN- CA- and DEN- CA+ groups. DEN+ CA- and DEN+ CA+ groups clustered 
together and showed low levels of signature gene expression. However, DEN+ CA+ treated 
animals, the group with the most severe tumor progression, had the lowest levels of HNF4a gene 
signature expression (Figure 3.4.2).  
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Figure 3.4.2. Decreased Expression of HNF4a Signature Genes Correlates with 
Advancement of HCC Severity in Mice. Hierarchical clustering of signature expression 
patterns indicates decreased HNF4a activity in mice with DEN-induced HCC (DEN+ CA-, 
DEN+ CA+) when compared to untreated mice (DEN- CA-) or mice treated with only cholic 
acid (DEN- CA+). A further decrease in activity was observed in mice with cholic acid promoted 
HCCs (DEN+ CA+). 
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3.4.3. In Silico Analysis of HNF4a Target Gene Signature Expression in Human Samples 
Next, we tested if decreased HNF4a activity in human samples, as measured by signature gene 
expression, would correlate with advancement of HCC. We analyzed expression of signature 
genes in publicly available human liver cancer data sets (Yildiz et al., 2013). The first data set 
consisted of 37 samples consisting of cirrhotic liver or HCC (Figure 3.4.3A). Clustering analysis 
identified 2 clusters with opposite expression patterns. The first cluster, outlined in red, 
expressed high levels of signature genes (73% or 19/26), which were primarily cirrhotic samples. 
The second cluster, outlined in blue, expressed low levels of signature genes (91% or 10/11) and 
had primarily of HCC samples. The second data set consisted of patient-paired normal liver and 
tumor tissue from 10 human patients (Figure 3.4.3B). Clustering analysis identified 2 clusters 
with opposite expression patterns. The first cluster, outlined in red, expressed high levels of 
signature genes and contained primarily (90% or 9/10) the paired normal liver tissue. The second 
cluster, outlined in blue, expressed low levels of signature genes and contained primarily (90% 




Figure 3.4.3. Expression of HNF4a Signature Genes Distinguishes HCC Samples from 
Cirrhotic or Normal Tissue Expression Patterns. (A) Comparison of signature gene 
expression in a dataset of 37 human cirrhosis and HCC samples revealed decreased HNF4a 
activity is observed in cluster consisting primarily HCC samples. (B) Hierarchical clustering of 
signature expression patterns in sample set of 10 patient-paired normal and liver tumor tissue 
distinguished between normal tissue (high expression) from liver tumor tissue (low expression). 
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The third data set consisted of 75 human samples of various histopathological findings including 
normal liver, cirrhotic liver tissue, low-grade dysplasia, high-grade dysplasia, very early HCC, 
early HCC, advanced HCC, and very advanced HCC (Figure 3.4.4) (Wurmbach et al., 2007). 
Clustering analysis identified 2 clusters with opposite expression patterns. The first cluster, 
outlined in red, expressed high levels of signature genes and only 2% (1/44) of the samples 
included in this cluster belonged to advanced HCC while the remainder belonged to normal liver, 
cirrhotic liver, low grade dysplasia, high grade dysplasia, or very early HCC. Within the first 
cluster was a subcluster with very high expression of signature genes (outlined with purple 
dotted line in the figure) that consisted exclusively of samples from normal liver tissue. The 
second cluster, outlined in blue, expressed low levels of signature genes and 52% (16/31) of the 
samples in this cluster belonged to advanced or very advanced HCC while the remainder 
belonged to early or very early HCC. Within the second cluster was a subcluster, outlined with 
green dotted line, with very low expression of signature genes. In this subcluster, 90% (9/10) of 
the samples belonged to advanced or very advanced HCC.  
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Figure 3.4.4. Decreased HNF4a Activity Correlates with Advancement of Human HCC. 
Hierarchical clustering of signature gene expression in 75 human samples revealed increased 
HNF4a activity in cluster of normal liver and pre-HCC samples (red outline) and decreased 
HNF4a activity in cluster consisting primarily of HCC (blue outline). A subcluster with very 
high HNF4a activity (dotted purple outline) included only normal liver samples and a subcluster 




3.4.4. In Vivo Analysis of HNF4a Target Gene Signature Expression in Human Cirrhotic and 
HCC Samples 
To further confirm the in silico data, we measured expression of HNF4a mRNA and HNF4a 
gene signature in a set of 5 cirrhotic liver and 5 HCC human patient samples. Expression of 
HNF4a mRNA was variable within each group (Figure 3.4.5A). Next, we performed TaqMan 
based qPCR analysis of the HNF4a gene signature followed by cluster analysis of the data. 
Clustering analysis of gene signatures identified 2 clusters with opposite expression patterns 
(Figure 3.4.5B). The first cluster, outlined in red, expressed high levels of signature genes. 3 of 4 
samples in this cluster belonged to cirrhotic samples. The second cluster, outlined in blue, 
expressed low levels of signature genes. 4 of 6 samples in this cluster belonged to HCC samples. 
On average, expression of signature genes was lower in HCC samples than cirrhotic samples 
(Figure 3.4.5C).  
 88 
 
Figure 3.4.5. Decreased HNF4a Activity in HCC Compared to Cirrhotic Samples. In a 
sample set of 5 cirrhotic and 5 HCC human samples (A) various levels of HNF4a mRNA 
expression was detected but was lower on average in samples with HCC. (B) Increased HNF4a 
activity was observed in a cluster of 75% cirrhotic samples (red outline) and decreased HNF4a 
was observed in a cluster of 60% HCC samples (blue outline). (C) HNF4a activity was lower on 
average in HCC samples compared to cirrhotic samples. 
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3.4.5. Correlation of HNF4a Target Gene Signature Expression with Histological Progression 
of HCC in Human Samples 
Next, we tested whether decreased HNF4a target gene signature expression would correlate with 
histological progression of HCC. Dr. Maura O’Neil, a board-certified pathologist used 
histological features from H&E stained sections to classify 16 human liver samples into discrete 
stages of HCC progression. From least advanced to most advanced disease, the stages were 
“Regenerative Nodule”, “Dysplasia”, “Well-Differentiated HCC”, and “Moderately-
Differentiated HCC”. Duplicate sections from the same samples were stained for HNF4a 
immunohistochemistry, which revealed a variety of staining patterns (Figure 3.4.6A). The 
normal tissues showed strong nuclear staining only in hepatocytes. The patient samples showed 
various patterns including decreased nuclear staining, both nuclear and cytoplasmic staining, 
only strong cytoplasmic staining and almost complete loss of HNF4a staining. Although many 
of the staining patterns were abnormal when compared to normal liver, no correlation was found 
between HNF4a staining pattern and stage of HCC progression. We obtained total RNA from 
the same samples, which was used to measure expression of HNF4a signature genes using 
TaqMan arrays. The data showed that dysplastic nodules had most ‘normal’ gene expression 
pattern while the regenerative nodules has a significantly decreased HNF4a target gene 
expression. Further, downregulation of a majority of signature genes was observed in well-
differentiated and moderately differentiated HCC. The moderately differentiated HCC samples 
exhibited the most significant decrease in HNF4a target gene expression. Finally, the HNF4a 
staining patterns did not correlate with signature outcomes.  
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Figure 3.4.6. HNF4a Target Gene Signature Correlates with Histological Staging of HCC 
Better than HNF4a Staining. In a sample set of 16 human tumor samples of various stages in 
advancement (A) immunohistochemical staining for HNF4a revealed a variety of staining 
patterns among the samples which did not correlate with tumor staging. (B) HNF4a activity was 




3.4.6. HNF4a Gene Signature is Correlated With Clinical Outcome.  
To determine if final clinical outcome of HCC is correlated with HNF4a gene signature, we 
performed cluster analysis of expression data and survival data of 365 independent HCC cases 
obtained from the TCGA database. Cluster analysis (Figure 3.4.7A) distributed the samples in 
two main clusters, one with significantly higher HNF4a target gene expression (group 1, blue, 
279 samples) and second with a significantly lower HNF4a gene expression pattern (group 2, 
yellow, 86 samples). A Kaplan-Meier plot of the groups showed that Group 1, which had 
significantly higher HNF4a target gene signature showed significantly better survival 
(p=0.0001) over 3500 days (9.5 years).  
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Figure 3.4.7. High Expression HNF4a Signature Genes is Predictive of Survival. (A) 365 
human samples were divided into 2 groups using K-means clustering. Group 1 consisted of 
samples with high HNF4a activity and Group 2 consisted of samples with low HNF4a activity. 
(B) Kaplan-Meier plot of these groups indicated significantly decreased survival of Group 2 




There is substantial evidence that HNF4a expression is downregulated in cancers of the gut, 
kidney and liver (W. Y. Cai et al., 2017; Chellappa, Jankova, et al., 2012; Chellappa, Robertson, 
& Sladek, 2012; Hatziapostolou et al., 2011; Ning et al., 2010; Sel et al., 1996; Tanaka et al., 
2006; Walesky, Edwards, et al., 2013; C. Yin et al., 2008). Further, studies in rodent models 
have shown that HNF4a reexpression may be used as ‘differentiation therapy’ in HCC. Whereas 
these studies indicate that HFN4a is an anti-tumor nuclear receptor, the exact mechanisms are 
not known. Furthermore, if HNF4a can be used as a prognostic tool in cancer pathogenesis has 
not been investigated. The hypothesis driving this study was that a decrease in HNF4a activity 
occurs during disease progression from normal liver to cirrhosis and further to HCC and also 
during further progression of HCC to more advanced stages. Evidence showing loss of HNF4a 
activity drives HCC pathogenesis comes from a variety of sources. Decrease in HNF4a 
expression results in decrease of hepatocyte differentiation, which could be further related to 
increased rates of proliferation and increased HCC aggressiveness (Lazarevich et al., 2004). By 
identifying the HNF4a target gene signature, our objective was to develop a tool that could 
measure HNF4a activity so that the loss of HNF4a activity that occurs during HCC progression 
could be observed.  
 
We defined HNF4a activity as expression of HNF4a target genes. By defining HNF4a activity 
as expression of HNF4a target genes, we could measure activity independently of changes in 
mRNA transcript sequence or antigen availability, which can confound results obtained using 
qPCR or antibody detection of protein, such as IHC or western blotting. Our studies indicate that 
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measuring HNF4a protein or mRNA expression does not reflect HNF4a activity. We observed a 
variety of HNF4a staining patterns, none of which correlated with either HNF4a activity 
measured by target gene expression or the HCC pathogenesis. The varied staining pattern may be 
due to either posttranslational modification of HNF4a protein or due to presence of more than 
isoforms of HNF4a or the combination of both. Multiple post-translational modifications are 
known for HNF4a but it is not known how those might affect activity. Also, multiple mRNA 
transcripts code for different isoforms of HNF4a and differences in activity between these 
isoforms is not well understood in the liver.  
We used an unbiased, global approach to identify the genes contained in the signature. Because 
HNF4a regulates 60% of all hepatocyte specific genes, the challenge with this approach was to 
select only for those genes that are direct targets with significant and reliable changes in 
expression based on HNF4a activity that are also relevant to the pathogenesis and advancement 
of HCC. Comparing gene expression changes between WT and HNF4a-KO normal livers, we 
identified novel positive and negative target genes of HNF4a. We were specifically interested in 
circumstances where decreased HNF4a activity led to HCC formation. Not all cancers will 
exhibit decreased expression of HNF4a, but we wanted to identify the patterns of gene 
expression characteristic of cancers with low HNF4a activity. Analysis of gene expression 
changes between WT and HNF4a-KO HCC tumors selected for direct and indirect targets whose 
expression is dependent on HNF4a in the cancer setting. Genes common between both of these 
analyses were robust direct and indirect HNF4a targets. These common genes were compared to 
HNF4a ChIP-Seq data to select for direct targets of HNF4a. HNF4a operates as part of a 
hepatic transcription factor network to maintain hepatocyte gene expression, which allows 
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HNF4a to indirectly control expression of many genes. These indirect targets are susceptible to 
expression changes caused by changes in activity from other transcription factors. By identifying 
direct HNF4a targets, the genes contained in the signature are not susceptible to this type of 
interference and can be considered a direct output of HNF4a function. In order for analysis of 
signature genes to take place using qPCR, the 323 gene signature was refined using IPA analysis 
to identify genes known to be involved in HCC. The signature was developed using mice, so 
only genes that were also found in humans were included in the final 44 gene signature. 42 of the 
44 signature genes are activated by HNF4a. The 2 negative targets, ITGA2 and CYP39A1, were 
included as inverse verification of HNF4a activity. 
 
Our analysis HCCs observed in the DEN-initiated cholic acid promoted HCC confirmed the 
ability of the signature to measure HNF4a activity and confirmed the hypothesis that decreased 
HNF4a activity occurs with advancement of HCC. We then tested this hypothesis using human 
gene expression data sets in silico. Clustering analysis of HNF4a gene signatures was capable of 
distinguishing cirrhotic samples from HCC samples based on the decreased HNF4a activity 
found in the latter (Figure 3.4.3A). The same was true when applied to patient-paired normal 
liver and tumor samples (Figure 3.4.3B). Finally, human HCCs of more advanced stage show the 
lowest HNF4a activity compared to normal or less advanced HCCs (Figure 3.4.4). From these 
analyses, we can conclude that HNF4a activity is lower in HCC than in normal liver, cirrhotic 
liver, and less advanced HCC.  
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Our data indicate that HNF4a activity is lower in HCC samples than cirrhotics on average. 
Whereas variation in signature expression patterns is expected, our data shows that the loss of 
HNF4a activity will lead to loss of hepatocyte function resulting in liver decompensation. This is 
consistent with previous findings that overexpression of HNF4a can improve survival in rodent 
studies (T. Nishikawa et al., 2015).  
 
Our analysis also examined how expression of signature genes correlated with HNF4a protein 
staining and disease progression as determined by histology. Previous studies have reported 
dysregulated HNF4a staining patterns in HCC. Accurate staging of HCC currently relies on 
histological analysis of biopsy material. We observed decreased HNF4a activity in sample 
groups with HCC. Previous studies have reported dysregulated HNF4a staining patterns in HCC. 
We observed similar variations in HNF4a staining in our samples, but these staining patterns did 
not correlate with disease stage or HNF4a activity. 
 
Finally, the most important finding of our study was that HNF4a gene signature analysis was 
clearly able to predict patient outcome. Our data shows that patients with higher target gene 
expression indicating significantly higher HNF4a activity have a substantially longer survival 
over a 9.5 year period. These data indicate that these patients are better able to maintain liver 
function and may be able to cope better with treatments. Use of the HNF4a target gene signature 
could be used to address some of the weaknesses present in current HCC treatment strategies. 
The BCLC therapeutic strategy and staging system is a widely accepted, evidence-based 
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algorithm used to determine treatment for HCC patients based on tumor stage (Bruix et al., 2015; 
J. M. Llovet, Bru, & Bruix, 1999; J. M. Llovet et al., 2016). This staging system uses Child-Pugh 
and ECOG scores as well as size and number of tumor nodules to determine HCC stage. These 
scoring systems rely on outputs of liver function and patient well-being and do not take into 
consideration the molecular drivers of the disease. Classification of HCCs based on HNF4a 
activity might result in more accurate staging methods or therapies targeting restoration of 
HNF4a transcriptional activity. Our results show more advanced HCCs have less HNF4a 
activity than less advanced HCCs. In patients diagnosed with HCC, those with low HNF4a 
activity could be given higher priority for curative therapies such as liver transplantation. HCCs 
must be diagnosed during the asymptomatic “Very Early” or “Early” stages if curative therapy is 
to be an option. Thus, screening of patients most at risk of developing HCC could improve 
chances of early diagnosis when the HCC is in a curable stage. 
 
 Due to study design, we cannot claim that decreased HNF4a activity is predictive of which 
cirrhotic patients will progress to HCC. However, we did observe lower levels of HNF4a 
activity in HCCs compared to cirrhotic patients in Figure 3.4.3 to Figure 3.4.5, indicating that 
loss of HNF4a activity does occur in some cirrhotic patients that develop HCC. Cirrhotic patients 
face risk of developing HCC as well as decompensating. Loss of HNF4a activity can promote 
progression to either of these disease states. Use of the signature in cirrhotic patients could be a 
screening method to identify patients at higher risk of developing HCC and decompensating. Our 
data suggest follow up studies could be done to determine if low HNF4a signature gene 
expression is predictive of HCC development or decompensation in cirrhotic patients. 
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Here we present a novel target gene signature capable of measuring HNF4a activity in humans 
and mice. The method used to develop this signature could be used to develop target gene 
signatures for other transcription factors. Measurement of HNF4a signature genes in a variety of 
scenarios revealed decreased HNF4a activity occurring in HCC compared to normal tissue. We 
also observed decreased HNF4a activity in HCCs of increasing advancement. This study offers 
evidence that classification of HCCs based on HNF4a activity may refine current HCC staging 
systems and provide additional tools for screening and diagnosis. Decreased HNF4a activity 
occurs in a majority of HCCs and restoration of HNF4a activity may be a new therapeutic 
strategy.  
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Chapter 4. Role of HNF4a in Systemic Energetics  
During Feeding Challenges 
Portions of this chapter have been previously published as a preprint and have not been peer-
reviewed. Huck, I., Morris, E. M., Thyfault, J. P., & Apte, U. (2018). Hepatocyte-Specific 
Hepatocyte Nuclear Factor 4 alpha (HNF4α) Deletion Decreases Resting Energy Expenditure By 





Hepatocyte Nuclear Factor 4 alpha (HNF4a) is required for hepatocyte differentiation and 
regulates expression of genes involved in lipid and carbohydrate metabolism including those that 
control VLDL secretion and gluconeogenesis. Whereas previous studies have focused on specific 
genes regulated by HNF4a in metabolism, its overall role in whole body energy utilization has 
not been studied. In this study, we used indirect calorimetry to determine the effect of 
hepatocyte-specific HNF4a deletion (HNF4a-KO) in mice on whole body energy expenditure 
(EE) and substrate utilization in fed, fasted, and high fat diet (HFD) conditions. HNF4a-KO had 
reduced resting EE during fed conditions and higher rates of carbohydrate oxidation with fasting. 
HNF4a-KO mice exhibited decreased body mass caused by fat mass depletion despite no change 
in energy intake and evidence of positive energy balance. HNF4a-KO mice were able to 
upregulate lipid oxidation during HFD suggesting that their metabolic flexibility was intact. 
However, only hepatocyte specific HNF4a-KO mice exhibited significant reduction in basal 
metabolic rate and spontaneous activity during HFD. Consistent with previous studies, hepatic 
gene expression in HNF4a-KO supports decreased gluconeogenesis and decreased VLDL export 
and hepatic b-oxidation in HNF4a-KO livers across all feeding conditions. Together, our data 
suggest deletion of hepatic HNF4a increases dependence on dietary carbohydrates and 
endogenous lipids for energy during fed and fasted conditions by inhibiting hepatic 
gluconeogenesis, hepatic lipid export, and intestinal lipid absorption resulting in decreased whole 
body energy expenditure. These data clarify the role of hepatic HNF4a on systemic metabolism 
and energy homeostasis.  
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4.2. Introduction 
The role of HNF4a in hepatic lipid and carbohydrate metabolism has been well recognized and 
was described in Chapter 1. Alterations in these pathways following HNF4a knockout would 
likely alter systemic metabolism but this has not been examined. The previous investigations 
have focused on the role of HNF4a in metabolism by examining hepatic gene expression, 
histology and serum metabolites. Despite its powerful effect on hepatic glucose and lipid 
metabolism, the exact role of hepatic HNF4a on systemic energy metabolism and substrate 
utilization patterns has not been examined. Here we used metabolic stressors of fasting and high 
fat diet (HFD) feeding combined with indirect calorimetry to examine how targeted hepatic 
deletion of HNF4a in adult mice effects systemic energy metabolism.  
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4.3. Materials and Methods 
4.3.1. Animal Care and Tissue Preparation 
All animal studies were approved by and performed in accordance with the Institutional Animal 
Care and Use Committee (IACUC) at the University of Kansas Medical Center. All mice were 
housed in temperature-controlled conditions (23°C) with a 07:00-21:00 h light phase and 21:00 
to 07:00 h dark phase. Two to three-month-old male homozygous HNF4a-floxed mice on 
C57BL/6J background were injected intraperitoneally with AAV8-TBG-eGFP or AAV8-TBG-
CRE resulting in wild-type (WT) and hepatocyte-specific deletion of HNF4a (HNF4a-KO). 
These vectors were purchased from Penn Vector Core (Philadelphia, PA) and injected as 
previously described (Yanger et al., 2013). Liver was harvested, weighed and flash frozen in 
liquid nitrogen at time of euthanasia.  
 
To study the effects of HNF4a deletion in fed and fasted conditions (Figure 4.4.1, Figure 4.4.3, 
Table 4.4.1), HNF4a-floxed littermates were injected with AAV8 to generate WT (n=4) and KO 
(n=4) groups and were housed individually for one week before entering metabolic cages. While 
in the cages mice were given ad libitum access to normal chow (PicoLab Rodent Diet 20 #5053, 
LabDiet, St. Louis, MO) for 6.5 days. Chow was removed, and mice were subjected to a 12-hour 
fasting challenge beginning at the start of the dark cycle. Chow was returned to the cages and 
mice were given 48 hours of ad libitum access to chow before euthanasia and tissue collection. 
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To study the change in energy metabolism and body composition during the process of HNF4a 
deletion (Figure 4.4.2, Table 4.4.2), HNF4a-floxed littermates were housed individually for 5 
days before entering metabolic cages. Mice were then acclimatized for 2 days to the indirect 
calorimetry cage conditions before being injected with AAV8 to generate WT (n=3) and 
HNF4a-KO (n=4) groups. Mice remained in the cages for 7 days post injection before 
euthanasia and tissue collection. 
 
To study the effects of HNF4a deletion in high fat diet (HFD) conditions, HNF4a-floxed 
littermates were individually housed, injected with AAV8 to generate WT (n=4) and HNF4a-KO 
(n=4) groups and fed a control diet containing normal fat content (10% kcal from fat, Cat.# 
D12110704, Research Diets, Inc., New Brunswick, NJ) for 1 week before entering indirect 
calorimetry cages. Mice were fed control diet for an additional 3 days in the indirect calorimetry 
cages before switching to a HFD (60% kcal from fat, catalog# D12492, Research Diets, Inc., 
New Brunswick, NJ) for 4 days before euthanasia and tissue collection. HFD was replaced every 
2 days to prevent spoilage.  
 
To study the role of HNF4a on energy metabolism during liver regeneration after partial 
hepatectomy (PH), HNF4a-floxed littermates were injected with AAV8 and individually housed 
for 4 days before entering metabolic cages. Mice were acclimatized for 2 days to the indirect 
calorimetry cage conditions before data collection started. Data were collected for 1 day prior to 
PH and 7 days after PH before euthanasia and tissue collection.  
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4.3.2. Indirect Calorimetry 
Indirect Calorimetry analysis was performed at the University of Kansas Medical Center 
Metabolic Obesity Phenotyping Facility using a Promethion continuous indirect calorimetry 
system (Sable Systems International, Las Vegas, NV) as previously described (Fletcher et al., 
2018). Macros available from the manufacturer were used to calculate total energy expenditure 
(TEE) based on the Weir equations (Weir, 1949) and respiratory quotient (RQ) by VCO2/VO2. 
To calculate resting energy expenditure (REE), the Promethion designed macro pulled out the 
lowest 30 min period of EE (light cycle) which was then extrapolated to a 24 hour period. The 
difference between TEE and REE was used to determine non-resting energy expenditure 
(NREE). Food was weighed before and after each experiment to determine food consumption. 
The mass of food consumed was used to determine energy intake (EI) based on the manufacturer 
provided values for metabolizable energy from each diet type and comparisons were made using 
body mass as a covariate for EI. Energy Balance (EB) was calculated by subtracting daily total 
energy expenditure from EI. These calculations were performed as previously described (Morris 
et al., 2014). Food hoppers were equipped with a sensor to determine food hopper interaction and 
manufacturer designed macros used this data to determine hourly feeding bouts. Activity was 
determined using the XYZ Beambreak Activity Monitor (Sable Systems, Las Vegas, NV) and is 
expressed as the sum of X and Y beam breaks per time period. Mice were given 2 days to 
acclimatize to new cages before data was recorded.  
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4.3.3. Serum Analysis 
Blood glucose was measured with a glucometer using blood collected via retroorbital sinus at 
time of euthanasia. Serum was isolated and commercially available kits were used to measure b-
Hydroxybutyrate (#2440-058, Stanbio), serum triglycerides (#T7532-500, Pointe Scientific) and 
serum free fatty acids (#MAK044, Sigma-Aldrich). 
 
4.3.4. Body Composition Analysis 
Body composition was performed prior to placement in indirect calorimetry cages and again 
before euthanasia using the EchoMRI-900 instrument (EchoMRI, Houston, TX). Mice were 
weighed by hand before entering indirect calorimetry cages, at injection times, before diet 
changes and before euthanasia. Fat-free mass was calculated by subtracting fat mass from body 
mass. Percent fat and percent fat free mass was calculated by dividing fat or fat free mass by 
body mass. Change in fat and fat-free mass was calculated by subtracting the value obtained at 
the start of the experiment from the value obtained before euthanasia. 
 
4.3.5. RT-PCR Analysis 
RNA from frozen liver was isolated using Trizol method and reverse transcribed to cDNA as 
previously described (Apte et al., 2009). Fold change values were calculated in comparison to 
WT-fed mice using the ddCt method as previously described (Livak & Schmittgen, 2001). Table 
4.3.1 contains primer sequences used in this study.  
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Table 4.3.1: Primer Sequences Used in This Study 
  Forward Primer (5' - 3') Reverse Primer (5' - 3') 
g6pase CCGGTGTTTGAACGTCATCT  CAATGCCTGACAAGACTCCA  
pepck TGCGGATCATGACTCGGATG  AGGCCCAGTTGTTGACCAAA  
pdk4 AGATTGACATCCTGCCTGACC TCTGGTCTTCTGGGCTCTTCT 
cpt1 GGACTCCGCTCGCTCATTC GAGATCGATGCCATCAGGGG 
cd36 ATGGGCTGTGATCGGAACTG GTCTTCCCAATAAGCATGTCTCC 
mttp CAAGCTCACGTACTCCACTGAAG TCATCATCACCATCAGGATTCCT 
 
4.3.6. Statistical Analysis 
Statistical analysis was performed using IBM SPSS Statistics Version 25. One Way ANOVA or 
Student’s t test was applied where indicated with p < 0.05 being considered significant. Analysis 
of energy expenditure and energy intake with body mass as a covariate was performed as 
previously described (Morris et al., 2014) and in accordance with published protocols 




4.4.1. Hepatocyte-Specific HNF4a-KO Mice Exhibit Decreased Resting Energy Expenditure 
During Fed Conditions. 
HNF4a-KO mice on a chow diet exhibited decreased total energy expenditure (TEE) at multiple 
time points throughout the dark and light cycle (Figure 4.4.1A). TEE and resting energy 
expenditure (REE) were also significantly lower in HNF4a-KO mice when data was 
summarized throughout the 24-hour cycle (data not shown). However, energy expenditure is 
influenced to a significant degree by body mass and multiple methods have been proposed for 
eliminating the contributing of body mass when comparing energy expenditure in organisms of 
different size (Tschop et al., 2011). To account for the impact of body mass on energy 
expenditure, TEE, REE, and non-resting energy expenditure (NREE) were calculated and 
analyzed with body mass used as a covariate (Figure 4.4.1B). In this experiment, random 
distribution of littermates into treatment groups resulted in individual differences in body mass, 
with some HNF4a-KO mice weighing more than their WT littermates. Since these mice also 
exhibited decreased unadjusted TEE, adjusting means with body mass as a covariate actually 
underestimated the decrease in EE in HNF4a-KO mice. The correction of EE with body mass as 
a covariate resulted in the adjusted TEE between WT and HNF4a-KO mice to be similar (Figure 
4.4.1B). However, REE values, which were adjusted for body mass, were significantly reduced 
in HNF4a-KO mice (Figure 4.4.1B). There were no differences in adjusted NREE between 
genotypes (Figure 4.4.1B). Respiratory quotient (RQ) in HNF4a-KO and WT mice was similar 
throughout the 24-hour cycle (Figure 4.4.1C). RQ remained similar between WT and HNF4a-
KO mice when the data was quantified for the entire light or dark cycle (Figure 4.4.1D, Left 
Panel). However, delta RQ, representing the difference in RQ between light and dark cycles, was 
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greater in HNF4a-KO mice and was nearly statistically significant with p = 0.06 (Figure 4.4.1D, 
Right Panel). Activity was measured by total X and Y beam breaks. No significant differences in 
activity were observed between WT and HNF4a-KO mice at any time point during the 24-hour 
cycle (Figure 4.4.1E) or when mean hourly beam breaks were summarized per light/dark cycle 
(Figure 4.4.1F). Daily energy intake (EI) was similar between groups (Figure 4.4.1G). Daily 
energy balance was similar between groups (Figure 4.4.1H). In summary, on a chow diet the 
hepatocyte-specific HNF4a-KO mice exhibited decreased resting energy expenditure. This 
occurred with only minor differences in substrate utilization and no differences in spontaneous 




Figure 4.4.1: Hepatocyte-specific HNF4a-KO mice exhibit decreased resting energy 
expenditure during fed conditions. Indirect calorimetry performed on WT and hepatocyte-
specific HNF4a-KO mice during 4.5 days of ad libitum normal chow feeding. (A) Mean hourly 
total energy expenditure in WT and HNF4a-KO mice over a 24-hour cycle. Raw values have not 
been adjusted for body mass differences. (B) Daily total energy expenditure, resting (REE) and 
non-resting (NREE) energy expenditure in WT and HNF4a-KO mice. Means adjusted with body 
mass (BM) used as a covariate for energy expenditure. (C) Mean RQ over a 24-hour cycle. (D, 
Left Panel) Mean RQ summarized by light and dark cycles. (D, Right Panel) Delta depicts the 
difference in RQ between light and dark cycles. (E) Activity of WT and HNF4a-KO mice 
expressed as the total X and Y beam breaks for each hour over a 24-hour cycle. (F) Activity of 
WT and HNF4a-KO mice expressed as the total X and Y beam breaks per hour and summarized 
per light and dark cycle. (G) Daily energy intake in WT and KO mice with BM used as a 
covariate. (H) Daily energy balance in WT and KO mice. Gray background indicates dark cycle 
time point. Values are means ± SEM. Statistical significance determined by one-way ANOVA 
between WT and KO with * indicating significance with p < 0.05 between WT and HNF4a-KO. 
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As mentioned previously, individual differences in body mass existed between mice, but there 
were no significant differences in mean body mass between WT and HNF4a-KO groups (Table 
4.4.1). There were no significant differences in food consumption (Table 4.4.1). HNF4a-KO 
mice had significantly less fat mass at the end of the experiment and lost a significant amount of 
fat mass over the 9 days of analysis compared to WT mice (Table 4.4.1). Fat-free mass was 
significantly greater in HNF4a-KO mice (Table 4.4.1). HNF4a-KO mice had significantly lower 
blood glucose compared to WT mice (Table 4.4.1).  
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Table 4.4.1: Body composition, food consumption and blood glucose data for WT and 
HNF4a-KO mice fed normal chow. Body mass, fat mass, and blood glucose were measured 
immediately before euthanasia. Food consumption values depict the mass of normal chow 
consumed during the entire feeding period and are presented as absolute values. Change in fat 
mass was calculated for each mouse by subtracting the total fat mass at the start of indirect 
calorimetry analysis from the fat mass measured immediately before euthanasia. Fat free mass 
was calculated by subtracting fat mass from body mass using values obtained immediately 
before euthanasia. Values are means ± SEM. Statistical significance determined by Student’s t-
test with * indicating significance with p < 0.05 between WT and HNF4a-KO. 
  WT KO 
Body Mass (g) 22.35 ± 0.52 23.45 ± 0.21 
Food Consumption (g) 24.38 ± 0.36 24.13 ± 1.08 
Fat Mass (g) 1.83 ± 0.13 1.16 ± 0.22* 
Change in Fat Mass (g) 0.25 ± 0.05 -0.17 ± 0.16* 
Fat Free Mass (g) 20.53 ± 0.61 22.29 ± 0.15* 




4.4.2. Changes in Energy Expenditure Observed During Hepatocyte-Specific HNF4a Deletion 
Time Course. 
In the experiments from Figure 4.4.1, mice were injected with AAV8 vector and 1 week was 
allowed for cre recombinase to induce HNF4a deletion before the mice were placed in the 
indirect system for a 2 day acclimation period. This 9-day time span between viral treatment and 
data collection produced uncertainty as to whether the reduced REE observed in HNF4a-KO 
mice was ultimately caused by deletion of HNF4a from hepatocytes, or was a compensatory 
response to long-term HNF4a deletion. To address this issue, we adjusted the timing of our 
study so HNF4a-floxed mice were placed into the indirect calorimetry cages for 2 days before 
being injected with AAV8. EE, RQ and activity was measured for a 7-day time course following 
injection of AAV8 into mice. If the decreased REE phenotype observed in HNF4a-KO mice was 
a direct result of HNF4a deletion, we expected REE to be the same between groups prior to 
AAV8 injection and REE to steadily decrease in mice injected with AAV8-TBG-CRE. As 
expected, TEE was similar between groups before AAV8 injection. However, TEE began to 
decrease in HNF4a-floxed mice after AAV8-TBG-CRE injection (Figure 4.4.2A), most notably 
during the light cycle. REE was calculated for WT and HNF4a-KO mice for the initial two days 
at the start of deletion and the final two days before euthanasia with body mass used as a 
covariate. REE in WT mice did not change over the experiment time course, but there was a 
significant decrease in HNF4a-KO over the deletion time course. (Figure 4.4.2B). Although 
statistically significant differences in REE between WT and HNF4a-KO at both time points 
were not observed, the trend of decreased REE during HNF4a deletion suggests that the decline 
in REE would continue in HNF4a-KO mice and become statistically significant over a longer 




Figure 4.4.2. Changes in energy expenditure observed during hepatocyte-specific HNF4a 
deletion time course. Indirect calorimetry performed on HNF4a-floxed mice before and 7 days 
after injection with AAV8-TBG-eGFP(WT) or AAV8-TBG-CRE (HNF4a-KO). (A) Mean 
hourly total energy expenditure (EE) for WT and HNF4a-KO mice before and after AAV8 
injection. Raw values have not been adjusted for body mass differences. (B) Resting EE (REE) 
in WT and HNF4a-KO mice at the start (first 2 days) and end (final 2 days) of the deletion time 
course. Means adjusted with body mass (BM) used as a covariate for energy expenditure. Gray 
background indicates dark cycle time point. Values are means ± SEM. Statistical significance 
determined by one-way ANOVA between WT and KO or between time points with * indicating 
p < 0.05 between WT and HNF4a-KO. 
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Food consumption was similar between treatments (Table 4.4.2). Body mass at time of 
euthanasia was similar between treatments, but HNF4a-KO mice lost significantly more body 
mass compared to WT mice from the time of AAV8 injection to euthanasia (Table 4.4.2). The 
decrease in body mass primarily occurred through a decrease in fat mass. Total fat mass was 
significantly lower in HNF4a-KO mice compared to WT at euthanasia and HNF4a-KO mice 
lost more total fat mass over the deletion time course compared to WT mice (Table 4.4.2). Fat-
free mass was similar between treatments (Table 4.4.2).  
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Table 4.4.2: Body composition data for WT and HNF4a-KO mice in acute deletion study. 
Body mass and fat mass were measured at the end of the deletion time course immediately 
before euthanasia. Food consumption values depict the mass of normal chow consumed 
throughout the entire deletion time course and are presented as absolute values. Change in fat 
mass was calculated for each mouse by subtracting the total fat mass measured before AAV8 
injection from the fat mass measured immediately before euthanasia. Fat free mass was 
calculated by subtracting fat mass from body mass using the values obtained immediately before 
euthanasia. Values are means ± SEM. Statistical significance determined by Student’s t-test with 
* indicating significance with p < 0.05 between WT and HNF4a-KO. 
 
WT KO 
Body Mass (g) 26.10 ± 0.83 24.78 ± 0.49 
Change in Body Mass (g) -0.17 ± 0.38 -1.40 ± 0.24* 
Food Consumption (g) 32.37 ± 0.92 33.35 ± 3.24 
Fat Mass (g) 1.70 ± 0.24 1.00 ± 0.13* 
Change in Fat Mass (g) -0.04 ± 0.03 -0.59 ± 0.08* 




4.4.3. HNF4a-KO Exhibit Elevated RQ During Fasting 
WT and HNF4a-KO mice were subjected to a 12-hour fasting challenge to determine how this 
would differently impact EE and substrate utilization. We found no significant differences in 
TEE between WT and HNF4a-KO mice at any time points throughout the fasting challenge 
(Figure 4.4.3A). The TEE, REE and NREE summarized throughout the 12 hour fast and adjusted 
using body mass as a co-variate also did not reveal differences (Figure 4.4.3B). However, we did 
find pronounced differences in substrate utilization in the HNF4a-KO mice compared to WT. 
HNF4a-KO mice had a much slower shift in lowering RQ during the fast compared to WT, 
suggesting a defect in the ability to upregulate the utilization of lipids for energy (Figure 4.4.3C). 
This metabolic inflexibility phenotype was likely due to a decreased availability of fatty acids 
from lipolysis as we observed depletion of adipose tissue after HNF4a deletion (Table 4.4.1, 
Table 4.4.2) and found reduced circulating FFA after fasting (Figure 4.4.5A). In addition, 
reduced fatty acid utilization could also occur because of reduced fat oxidation in the liver due to 
reduced CPT-1 expression, which is known to be reduced with HNF4a deletion (Figure 4.4.5B). 
Activity was not different between groups (Figure 4.4.3D).  
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Figure 4.4.3. HNF4a-KO mice exhibit elevated RQ during fasting. (A) Mean hourly total 
energy expenditure (EE) during 12-hour fast. Raw values have not been adjusted for body mass 
differences. (B) Total EE, resting EE (REE) and non-resting EE (NREE) during 12-hour fast. 
Means adjusted with body mass (BM) used as a covariate for energy expenditure. (C) Mean 
hourly RQ during 12-hour fast. (D) Activity during 12-hour fast expressed as total X and Y beam 
breaks per hour. Values are means ± SEM. Statistical significance determined by one-way 
ANOVA with * indicating p < 0.05 between WT and HNF4a-KO. 
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4.4.4. HNF4a-KO Mice Exhibit Decreased Energy Expenditure, Decreased RQ, Decreased 
Activity and Loss of Body Mass During Acute High Fat Diet (HFD) Challenge.  
The metabolic inflexibility displayed by the HNF4a-KO mice to a fasting challenge suggested 
hepatic HNF4a deletion reduces whole body capacity for lipid utilization. To test the ability of 
HNF4a to obtain energy from lipids, we monitored energy expenditure, substrate utilization, 
activity and body composition in WT and HNF4a-KO mice before and after the initiation of a 
diet containing 60% kcal from fat (HFD). HNF4a-KO mice tended to have lower total EE before 
HFD feeding. However, total EE was reduced further in HNF4a-KO mice upon HFD feeding 
(Figure 4.4.4A). Significant reductions in total EE, REE and NREE were observed in HNF4a-
KO mice when body mass was used as a covariate (Figure 4.4.4B). Contrary to the metabolic 
inflexibility observed in HNF4a-KO mice during the fasting challenge, RQ of both groups 
decreased at the same rate upon initiation of HFD feeding. Further, RQ of HNF4a-KO mice was 
lower than WT mice at several time points throughout HFD feeding suggesting HNF4a-KO 
mice had greater capacity for or increased reliance on dietary lipid utilization when consuming a 
HFD (Figure 4.4.4C-D). Dark cycle activity was significantly reduced in HNF4a-KO mice 
compared to WT when measured by total X and Y beam breaks (Figure 4.4.4E) as well as 
feeding bouts (Figure 4.4.4F). Feeding bouts were determined by a manufacturer provided 
macro, and say more about activity than food consumption, since food intake rate and total food 
consumption as determined by macros was similar between groups (data not shown). 
Furthermore, food was weighed by hand at the start and end of the experiment and while 
HNF4a-KO mice consumed significantly less HFD (Table 4.4.3), energy intake was similar 
between groups when body mass was used as a covariate for food consumption (Figure 4.4.4G). 
Energy balance was similar between groups and positive in both groups (Figure 4.4.4H). Body 
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mass of WT and HNF4a-KO mice was similar at start of HFD feeding and at euthanasia (Table 
4.4.3). However, HFD feeding led to significantly different changes in body mass with a 7.7% 
increase in WT body mass and a 6.2% decrease in HNF4a-KO body mass (Table 4.4.3). While 
comparison of body mass between groups revealed no significant differences, the changes in 
body mass occurring during HFD feeding were significant for both genotypes and were 
confirmed using the in-cage body mass sensors (Figure 4.4.4I).  
 
HNF4a-KO mice contained significantly less fat mass than WT mice after HFD feeding (Table 
4.4.3). Comparison of the change in fat mass before and after HFD was similar between groups 
(Table 4.4.3). Fat free mass was similar between WT and HNF4a-KO mice (Table 4.4.3). Blood 
glucose was significantly lower in HNF4a-KO mice compared to WT mice, reflective of 
impaired gluconeogenesis (Table 4.4.3).  
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Figure 4.4.4. HNF4a-KO mice exhibit decreased energy expenditure, decreased RQ, 
decreased activity and loss of body mass during acute high fat diet (HFD) challenge. (A) 
Mean hourly total energy expenditure (EE) during the transition from normal chow to HFD. Raw 
values have not been adjusted for body mass differences. (B) Total EE, resting EE (REE) and 
non-resting EE (NREE) in WT and HNF4a-KO mice fed HFD. Means adjusted with body mass 
(BM) used as a covariate for energy expenditure. (C) Mean hourly RQ during transition from 
normal chow to HFD. (D) Mean RQ during HFD summarized by light and dark cycles. (E) 
Activity in HFD fed WT and HNF4a-KO mice during light and dark cycles expressed as the 
total X and Y beam breaks per hour. (F) Hourly feeding bouts during light and dark cycle in WT 
and HNF4a-KO fed HFD. (G) Daily energy intake in HFD fed WT and HNF4a-KO mice. 
Means adjusted with body mass used as a covariate for energy intake. (H) Daily energy balance 
in HFD fed WT and HNF4a-KO mice. (I) Average body mass in WT and HNF4a-KO mice 
during transition from normal chow to HFD. Gray background indicates dark cycle time points. 
Values are means ± SEM. Statistical significance determined by one-way ANOVA with * 
indicating significance with p < 0.05 between WT and HNF4a-KO. 
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Table 4.4.3: Body composition, food consumption, and blood glucose data for WT and 
HNF4a-KO mice subjected to acute HFD challenge. HFD body mass was measured when the 
mice started to feed on HFD. End body mass was measured after 4 days of HFD feeding and 
immediately before euthanasia. Consumption of HFD represents the total amount consumed 
throughout the HFD feeding period and are presented as absolute values. Fat mass was measured 
before euthanasia. Change in fat mass was calculated for each mouse by subtracting the fat mass 
measured before indirect calorimetry analysis from the fat mass measured before euthanasia. Fat 
free mass was calculated by subtracting fat mass from body mass using the values obtained 
immediately before euthanasia. Blood glucose was measured immediately before euthanasia. 
Values are means ± SEM. Statistical significance determined by Student’s t-test with * indicating 
significance with p < 0.05 between WT and HNF4a-KO. 
  WT KO 
HFD Body Mass (g) 21.83 ± 1.74 20.90 ± 1.14 
End Body Mass (g) 23.50 ± 1.62 19.60 ± 0.77 
Difference between HFD Body Mass and End 
Body Mass (g) 1.68 (7.7%) ± 0.33 -1.30 (-6.2%) ± 0.45* 
HFD Consumed (g) 11.70 ± 0.51 9.30 ± 0.78* 
Fat Mass (g) 2.84 ± 0.44 1.40 ± 0.11* 
Change in Fat Mass (g) 1.03 ± 0.51 0.17 ± 0.18 
Fat Free Mass (g) 20.66 ± 1.19 18.20 ± 0.72 
Blood Glucose (mg/dL) 200.00 ± 32.97 112.00 ± 6.36* 
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4.4.5. Changes in Serum Lipids and Hepatic Gene Expression in WT and HNF4a-KO Mice 
Across Feeding Conditions. 
To understand the metabolic phenotype characterized using indirect calorimetry, we measured 
serum lipids, ketones and hepatic expression of lipid and carbohydrate metabolism genes in WT 
and HNF4a-KO mice during fed, fasted and HFD conditions. Serum triglycerides and serum free 
fatty acids were significantly lower in HNF4a-KO animals in all conditions (Table 4.4.3A). No 
significant differences in serum ketones were observed between WT and HNF4a-KO mice 
(Table 4.4.3A). Gene expression for the rate limiting enzymes in gluconeogenesis (G6Pase, 
PEPCK) were decreased in HNF4a-KO mice in all conditions as expected given their lower 
glucose levels (Table 4.4.3B). PDK4, an enzyme involved in conservation of glucose and 
upregulation of lipid utilization, was elevated in HNF4a-KO mice in all conditions (Table 
4.4.3B). CPT1, the rate limiting enzyme for fatty acid entry into the mitochondria and 
subsequent b-oxidation, was suppressed in HNF4a-KO mice in all conditions (Table 4.4.3C). 
Expression of the hepatic lipid importer CD36 was elevated in HNF4a-KO mice in all 
conditions (Table 4.4.3C). Expression of the apolipoprotein packaging enzyme MTTP was 
suppressed in HNF4a-KO mice in all conditions (Table 4.4.3C). Thus, gene expression profiles 
of the livers from the HNF4a-KO are suggestive of impaired gluconeogenesis and enhanced 
lipid uptake paired with reduced capacity to oxidize and export lipids.  
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Figure 4.4.5. Changes in serum lipids and hepatic gene expression in WT and HNF4a-KO 
mice across feeding conditions. (A) Serum quantification of (left to right) triglycerides (TG), 
free fatty acids (FFA) and b-hydroxybutyrate (Ketones). Hepatic expression of genes involved in 
(B) glucose metabolism and (C) lipid metabolism and trafficking. Gene expression expressed as 
fold change compared to WT mice fed normal chow. Values are means ± SEM. Statistical 
significance determined by one-way ANOVA with * indicating significance with p < 0.05 
between WT and HNF4a-KO.  
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4.5. Discussion 
The role of HNF4a in hepatocyte differentiation and quiescence is well recognized (Duncan et 
al., 1994; Kyrmizi et al., 2006; J. Li et al., 2000; Morimoto et al., 2017; Parviz et al., 2003). 
HNF4a regulates several liver specific functions including lipid and carbohydrate metabolism, 
but our understanding of the role of HNF4a in metabolism is limited to its role in regulating 
hepatic gene expression and hepatic nutrient storage. Whether HNF4a mediated regulation of 
hepatic metabolism results in changes to systemic energetics has not been studied, which was the 
focus of these studies. 
 
The major finding of this study was that deletion of HNF4a from hepatocytes results in 
decreased resting energy expenditure during fed conditions. Additionally, hypoglycemia, body 
mass decrease, and decreased adiposity were observed in HNF4a-KO mice in all feeding 
conditions. The origin of these phenotypes was directly linked to decreased  hepatic HNF4a 
levels by examining mice during a 7-day time course of hepatic HNF4a deletion. The 
differences in energy expenditure between WT and HNF4a-KO mice were exaggerated during 
HFD feeding, with HNF4a-KO mice exhibiting significant decreases in total, resting, and non-
resting energy expenditure as well as decreased spontaneous activity. 
 
Reductions in energy expenditure caused by hepatic HNF4a deletion cannot be attributed to 
decreased energy intake. HNF4a-KO mice exhibited positive energy balance that was similar to 
WT energy balance during all feeding conditions. Despite exhibiting positive energy balance, 
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HNF4a-KO mice consistently exhibited decreases in body mass which were caused by depletion 
of fat mass. While it is not clear how HNF4a-KO mice lose body mass while maintaining 
positive energy balance, it could be explained by poor intestinal lipid absorption due to 
decreased bile acid production. It is well known that HNF4a regulates genes involved in bile 
acid synthesis, conjugation and transport (Hayhurst et al., 2001; Y. Inoue et al., 2004; Y. Inoue, 
Yu, et al., 2006). Cyp7a1, Cyp27a1 and Cyp8b1 are all positively regulated by HNF4a and 
exhibit decreased expression in HNF4a-KO mice (Y. Inoue, Yu, et al., 2006). As a result, 
HNF4a-KO mice synthesize fewer bile acids and excrete fewer bile acids in feces (Y. Inoue, Yu, 
et al., 2006). Basal expression of Cyp7a1 requires HNF4a and LRH-1 (Kir et al., 2012). Like 
HNF4a, LRH-1 also regulates Cyp8b1 and liver specific deletion of LRH-1 decreases Cyp8b1 
expression resulting in decreased bile acid production and poor intestinal lipid absorption 
(Mataki et al., 2007). It is highly probable that decreased bile acid synthesis in HNF4a-KO mice 
produces a similar phenotype of reduced intestinal lipid absorption. This would cause HNF4a-
KO mice to have increased dependence on endogenous adipose stores for lipid fuel molecules. 
This is supported by the increased lipolysis observed in HNF4a-KO mice throughout all 
experiments, including HFD challenge, which was so severe that adipose tissue from epididymal 
fat pads could not be collected from HNF4a-KO mice. Impaired availability of dietary lipids and 
dependence on endogenous lipids would also explain the dramatic reductions in HNF4a-KO 
energy expenditure and activity observed when the majority of dietary caloric intake was 
available as lipids during the HFD challenge, as well as their resistance to HFD-induced 
increases in adiposity. Decreased lipid absorption would result in an overestimation of energy 
intake in HNF4a-KO mice since energy intake was calculated using the mass of food consumed. 
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If the energy actually absorbed by the intestines could be calculated, HNF4a-KO energy balance 
would likely be negative and reflect the observed loss in body mass. 
 
Decreased availability of dietary lipids for energy production could affect metabolic activity in 
peripheral lean tissue. Serum triglycerides and free fatty acids were decreased in HNF4a-KO 
mice in all feeding conditions consistent with previous publications (Hayhurst et al., 2001; 
Martinez-Jimenez et al., 2010; L. Yin et al., 2011). These studies attribute decreased VLDL 
secretion in HNF4a-KO mice to decreased expression of MTTP and ApoB, which we also 
observed in all feeding conditions. Decreased hepatic VLDL secretion, combined with depletion 
of adipose tissue after long term HNF4a deletion, would effectively starve peripheral lean tissue 
of lipid energy molecules, resulting in decreased energy expenditure. 
 
Additional explanations exist for why we observed decreased energy expenditure after hepatic 
HNF4a deletion. HNF4a regulates hepatic CPT1a, the enzyme involved in the rate limiting step 
of fatty acid oxidation, during fed and fasted conditions (Martinez-Jimenez et al., 2010). CPT1a 
was downregulated in HNF4a-KO mice across all feeding challenges in the current study. It has 
been estimated that liver accounts for 20% of total EE (Ramsey, Harper, & Weindruch, 2000), so 
decreased capacity for hepatic b-oxidation could result in a detectable reduction in whole body 
energy expenditure. Decreased hepatic b-oxidation would increase RQ, opposite of what was 
observed in HNF4a-KO mice. However, this increase in RQ is likely masked the decreased RQ 
of peripheral tissues which would be forced to metabolize lipids in a hypoglycemic environment. 
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It has been shown that during cold exposure, activation of HNF4a is required for hepatic 
synthesis of acyl-carnitines which are used as fuel in brown fat thermogenesis (Simcox et al., 
2017). The mice in our study were housed at 24°C. While this is not cold exposure, it could be 
considered a source of minor thermoregulatory stress (Tschop et al., 2011). If hepatic HNF4a 
deletion results in reduced acyl-carnitine synthesis, brown adipose tissue in HNF4a-KO mice 
would be starved of energy molecules required for thermogenesis and therefore be less 
metabolically active, resulting in decreased energy expenditure. 
 
A previously unknown phenotype of hepatocyte-specific HNF4a deletion was reduction in fat 
mass. In all experiments with normal chow fed mice, depletion of adipose in HNF4a-KO mice 
drove a decrease in body mass. Additionally, HNF4a-KO mice were resistant to HFD-induced 
increases in body mass and adiposity. Increased lipolysis was likely caused by decreased 
availability of dietary lipids, but could also be caused by increased glucagon signaling in the 
hypoglycemic HNF4a-KO mice. Long term, this could result in near total lipolysis of adipose 
therefore preventing a fasting induced increase in serum FFA, such as what was observed in 
fasted HNF4a-KO mice. White adipose tissue is metabolically active itself and it has been 
shown to increase energy expenditure in lean tissue via leptin signaling (Kaiyala et al., 2010). 
Because HNF4a-KO mice are leaner, leptin signaling is likely lower, which would decrease 
energy expenditure in lean tissue. 
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Peripheral tissues of HNF4a-KO mice had decreased access to lipid energy molecules, but were 
also starved of glucose which could contribute to decreased energy expenditure. In all 
conditions, HNF4a-KO mice were significantly hypoglycemic. HNF4a is required for PGC1a 
mediated gluconeogenesis by co-activating PEPCK and G6Pase (Rhee et al., 2003; Yoon et al., 
2001). Moreover, hepatic fat oxidation, which is impaired in HNF4a-KO mice due to decreased 
CPT1a expression, is necessary for fueling gluconeogenesis. Indeed, PEPCK and G6Pase 
expression decreased in all feeding conditions following HNF4a deletion. Hepatocyte-specific 
HNF4a-KO mice exhibit depletion of hepatic glycogen (Walesky, Edwards, et al., 2013) which 
is likely caused by failed gluconeogenesis. Since liver is the primary gluconeogenic organ and 
HNF4a is required for hepatic gluconeogenesis, diet must be the exclusive source of 
carbohydrate for HNF4a-KO mice. Furthermore, if intestinal lipid absorption is impaired in 
HNF4a-KO mice, dietary carbohydrates would be especially important for energy production. 
This is supported by the decreases in total energy expenditure in HNF4a-KO mice during the 
deletion time course which occurred almost exclusively during the light cycle when mice reduce 
food consumption. Further, when availability of dietary carbohydrates was reduced, such as 
during HFD challenge, energy expenditure and activity are significantly reduced as HNF4a-KO 
mice must produce energy from a dwindling supply of endogenous lipid depots along with a 
liver exhibiting impaired gluconeogenesis. 
 
Substrate utilization data supports the hypothesis that HNF4a-KO mice depend exclusively on 
diet as a source glucose. During fed conditions, HNF4a-KO mice exhibited nearly significant 
increased oscillation between light and dark cycle RQ. Close inspection of RQ in Figure 4.4.1A 
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suggests a trend of increased dark cycle RQ and decreased light cycle RQ. Decreased light cycle 
RQ was also observed in HNF4a-KO mice before initiation of HFD feeding (Figure 4.4.4C). 
Elevated dark cycle RQ in HNF4a-KO mice can be explained by metabolism of dietary glucose 
consumed during the dark cycle feeding period in an organism with impaired VLDL secretion 
and exhausted adipose stores. During the light cycle, HNF4a-KO mice stopped feeding and 
quickly exhausted stored glucose, forcing them to use stored adipose resulting in reduced light 
cycle RQ. 
 
The most notable difference in substrate utilization between WT and HNF4a-KO mice was 
observed during the fasting challenge, where HNF4a-KO mice were slow to decrease RQ, 
suggesting a reluctance for HNF4a-KO mice to use lipids during caloric restriction. However, 
this was not supported by the HFD challenge, where HNF4a-KO did not have problems using 
lipids as a fuel source during HFD feeding and actually displayed lower RQ than WT mice 
during HFD feeding. The dependence on carbohydrates for fuel exhibited by fasted HNF4a-KO 
mice may not be caused by defective lipolysis or fatty acid oxidation, but rather be a product of 
deficient hepatic VLDL secretion and exhausted adipose stores following prolonged HNF4a 
deletion. This would force peripheral tissues to use any remaining carbohydrate for fuel during 
caloric restriction. As for substrate utilization during the HFD challenge, it is surprising that RQ 
was lower in HNF4a-KO mice considering dietary lipid absorption was likely reduced. HFD 
contained very low quantities of carbohydrates and gluconeogenesis was significantly inhibited 
in HNF4a-KO mice. Thus, options for energy sources in this scenario would be limited to 
endogenous lipids or residual intestinal lipid absorption. Also, increased ketogenesis could 
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explain the low RQ exhibited by HNF4a-KO mice during HFD feeding (Schutz & Ravussin, 
1980). Previous studies have shown increased ketosis in HNF4a-KO mice (Martinez-Jimenez et 
al., 2010), but we observed no differences between WT and HNF4a-KO serum b-
hydroxybutyrate. It is possible that ketone production was higher in HNF4a-KO mice during 
some phases of the dark cycle when RQ was below 0.7 but was not detectable in our samples 
which were collected during the light cycle. Another explanation could be the decrease in 
activity of HNF4a-KO mice fed HFD. While HNF4a-KO mice did not consume less energy 
than WT mice, reduced ambulatory activity during the feeding period translated into fewer dark 
cycle feeding bouts, which could result in lower RQ. 
 
Hypoglycemia and transient hepatic steatosis are well-known metabolic changes which occur 
after PH (J. Huang & Rudnick, 2014), but countering either can lead to inhibited liver 
regeneration. Several studies have shown that inhibiting hepatic steatosis after PH reduces 
hepatocyte proliferation (Fernandez et al., 2006; Kohjima et al., 2013; Shteyer et al., 2004) 
because accumulation of hepatic triglycerides is required to fuel b-oxidation in the regenerating 
liver (Bellet et al., 2016; Kachaylo et al., 2017; Kohjima et al., 2013; Mukherjee et al., 2017). 
Studies have also shown that inhibition of transient steatosis impairs liver regeneration by 
increasing expression of the HNF4a target gene p21 (Gazit et al., 2010; Weymann et al., 2009). 
These lipids come from lipolysis of adipose depots, and regeneration in lipid dystrophic mice 
which have decreased adipose stores, exhibit decreased hepatic steatosis and impaired liver 
regeneration (Gazit et al., 2010). This lipolysis is triggered by hypoglycemia, and 
supplementation with dextrose or glucose inhibits liver regeneration (Caruana, Whalen, 
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Anthony, Sunby, & Ciechoski, 1986; Weymann et al., 2009). However, besides one study which 
has shown an increase in lipid utilization during liver regeneration with indirect calorimetry in 
mice (Kachaylo et al., 2017), little is known about how these metabolic conditions can affect 
total energy expenditure or respiratory quotient. The preliminary results presented here have 
reproduced these findings, as we found WT mice to exhibit low RQ following PH. While none of 
the HNF4a-KO died in the 7 day regeneration time course of this study, noticeably lower energy 
expenditure throughout regeneration followed by a significant decline at the end of the time 
course provides further evidence that the mortality observed in these mice after PH is caused by 
failure of nutrient homeostasis due to decompensating liver. Further studies are needed to 
confirm these results. 
 
In conclusion, this study uses indirect calorimetry and targeted hepatic HNF4a deletion in adult 
mice to address unanswered questions regarding the role of hepatic HNF4a on systemic 
metabolic homeostasis and energy flux. Hepatocyte-specific HNF4a deletion reduces peripheral 
availability of energy molecules likely by reducing lipid absorption, hepatic VLDL secretion, 
and gluconeogenesis resulting in decreased resting energy expenditure. This study demonstrates 
how changes in hepatic HNF4a, a condition common in disease human liver (Baciu et al., 2017; 
Xu et al., 2015), can significantly impact whole body energy expenditure and availability of 
energy stores. This data will inform future attempts to target or modulate hepatic HNF4a by 
demonstrating its role in metabolism outside of the liver. Our findings reveal for the first time the 
impact of hepatic HNF4a on systemic energy flux and highlight the importance of liver as a 
central metabolic organ.  
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Chapter 5. Summary and Future Directions 
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Previous studies have shown HNF4a plays a central role in maintenance of hepatocyte function 
and suppression of hepatocyte proliferation. Decreased HNF4a expression and activity in the 
progression of liver disease makes it a promising target for therapeutic intervention. However, 
several questions about HNF4a biology had remained unanswered, which could be summarized 
as follows: Does HNF4a contribute to regulation of hepatocyte proliferation during liver 
regeneration? Does perturbed HNF4a activity during this process contribute to the initiation and 
advancement of liver disease? Is there a way to accurately measure the components of HNF4a 
activity which are relevant to the progression of liver disease? Can understanding HNF4a 
activity be used to accurately stage and prognosticate various forms of liver disease? If  
therapeutic targeting of hepatic HNF4a is performed, what are there consequences beyond the 
liver? Do changes to hepatic HNF4a during hepatocyte proliferation or during liver disease 
progression contribute to metabolic disturbances observed in these conditions? The studies 
presented in this dissertation were designed to answer these questions. While diverse methods 
and models were used, together our results provide new understanding of the role of HNF4a in 
liver biology and disease. 
 
5.1. HNF4a Required For Liver Regeneration 
Despite the well-recognized role of HNF4a in hepatocyte differentiation and quiescence, 
detailed studies on the role of HNF4a during liver regeneration were not performed. Using 
partial hepatectomy as a model of liver regeneration, we identified changes in nuclear HNF4a 
expression and activity during the initiation of liver regeneration. These changes occurred 
without changes to HNF4a transcription, repeating the findings of a previous study (Flodby et 
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al., 1993). This suggested regulation of HNF4a during liver regeneration was occurring at the 
post-translational level. Src kinase is known to phosphorylate HNF4a on Tyrosine-277 and 279 
and induce cytoplasmic translocation and proteasomal degradation in enterocytes (Chellappa, 
Jankova, et al., 2012). Indeed, inhibition of SRC increased nuclear levels of HNF4a after PH, 
suggesting that this is the mechanism by which HNF4a is regulated during liver regeneration. 
However, it is not clear what the impact of Src inhibition would be on proliferation over the 
regenerative time course or if other kinases could compensate for Src inhibition. Numerous 
examples of HNF4a regulation by PTMs exist outside of liver regeneration. HNF4a 
phosphorylation, ubiquitination and acetylation has been identified, and phosphorylation and 
acetylation has been shown to inhibit HNF4a transcriptional activity (Z. Wang et al., 2011; 
Yokoyama et al., 2011). Src is not the only kinase capable of phosphorylating HNF4a. 
Phosphorylation of HNF4a by Protein kinase C (PKC) on serine-78 in HepG2 cells decreases 
HNF4a nuclear localization, transcriptional activity and protein stability (K. Sun et al., 2007). 
Phosphorylation of HNF4a at serine 78 by PKC also occurs during the development of hepatic 
steatosis in HFD fed mice (Yu et al., 2018). Protein kinase A (PKA) can phosphorylate HNF4a 
at serine-142 and decreased DNA binding (Viollet, Kahn, & Raymondjean, 1997; Z. Wang et al., 
2011). Treatment of HepG2 cells with thyroid stimulating hormone activates PKA leading to 
phosphorylation of HNF4a and decreased nuclear localization and transcriptional activity (Y. 
Song et al., 2015). In mice, loss of prostaglandin E2 (PGE2) signaling in the liver leads to 
overactivation of PKA, phosphorylation of HNF4a at serine-143, leading to decreased CYP7A1 
expression and decreased bile acid synthesis (Yan et al., 2017). Future studies are needed to 
examine the expression and activity of these kinases during liver regeneration. Experiments 
using transgenic mice will determine the role of these kinases in liver regeneration. Transgenic 
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mice expressing phospho-null or phosphomimetic mutated HNF4a will be used to see if this 
changes HNF4a activity after partial hepatectomy or the regenerative process.  
 
Deletion of HNF4a prevented hepatocytes from redifferentiating after PH providing evidence 
that death in these mice was due to hepatic failure. PH is used to study signals and mechanisms 
behind the innate ability of hepatocytes to proliferate. An advantage of this model is these signals 
can be studied without needing to consider toxicant-specific effects present in models of liver 
regeneration after acute chemical injury. This means the model may have more relevance to the 
abnormal hepatocyte proliferation, wound healing responses and changes in differentiation 
present during the progression of liver disease. Failure of hepatocytes to compensate for HNF4a 
deletion during regeneration is another demonstration of HNF4a as the central regulator in 
hepatocyte differentiation. Previous work has demonstrated cirrhotic decompensation is 
associated with decreased expression of several hepatic transcription factors (FoxA2, HNF1a, 
Cebpa, HNF4a). Reexpression of HNF4a alone is enough to restore expression of these 
transcription factors and restore hepatic function and reversing hepatic failure. Interestingly, 
expression of HNF4a from the reexpression vector was only temporary, but this was enough to 
reactivate the endogenous HNF4a gene permanently (T. Nishikawa et al., 2015). Our results 
suggest that decreased hepatic function is a normal part of the regenerative process, but it occurs 
only for a short time. If the liver is injured in pathologic conditions, the regenerative process may 
never fully terminate, resulting in permanently compromised hepatic function. Reexpression of 
HNF4a may be a good strategy to restore expression of not just HNF4a targets, but all genes 
targeted by hepatic transcription factors.  
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5.2. HNF4a Gene Signature and Disease Progression 
Numerous studies have reported decreased expression of HNF4a being associated with the 
progression of liver disease, specifically the development and advancement of HCC. While the 
quest for drugs or other methods to restore HNF4a expression in diseased livers is ongoing, we 
hypothesized that a tool which could measure HNF4a activity would have significant use in the 
diagnosis and prognosis of liver disease. Other gene signatures have been developed for similar 
uses which use a specific pathological feature or changes in expression of known oncogene 
targets to identify the genes to be included in the signature. We took a more hypothesis driven 
approach. Our method was blinded to these outcomes and instead was based on the hypothesis 
that HNF4a activity could be measured based on expression of its direct target genes, and that a 
subset of these genes would be specifically downregulated in carcinogenesis. Instead of relying 
on detection of specific staining patterns or expression of canonical carcinogenic genes, this 
signature provided a more robust, global approach towards detecting HNF4a activity. Also, by 
centering our gene signature around a specific transcription factor, any sample the signature 
determines exhibits low HNF4a activity could conceivably be treated with a therapy restoring 
HNF4a. In this way the signature could be used to prescribe therapy to targeting the molecular 
drivers specific to a patient’s disease.  
 
The workflow we used to identify genes in the HNF4a signature could also be used to identify 
signatures for other transcription factors in other diseases. Generation of other signatures 
depicting the activity of a targetable transcription factor could be used in conjunction with the 
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HNF4a signature and lead to more accurate prognosis, staging and treatment of multiple disease 
states. The role of HNF4a in hepatic metabolism and its role in regulating gene expression of 
secreted proteins allows for potential for generation of a signature to measure HNF4a activity 
based on metabolites and biological material found in serum. This would allow for less invasive 
ways to measure HNF4a activity and could be used as an easily obtained biomarker of HCC or 
other liver conditions from a simple blood draw.  
 
Our study tested the signature in cirrhotic and HCC samples, but more studies are needed to 
determine if the signature could also be used to predict which cases of less advanced liver 
disorders (NAFLD, NASH, mild fibrosis) will progress into more severe forms. As detailed in 
the introduction, decreased expression of HNF4a occurs early on in these liver diseases. While 
mechanisms by which decreased HNF4a contributes to the pathogenesis of these diseases are 
known, it is not known if further downregulation of HNF4a is a mechanism pushing these 
conditions to a more advance stage of disease. 
 
Finally, the methods used to measure HNF4a activity in human and mouse tissues rely on a 
comparison between diseased samples and normal or less advanced tissues. While this is 
required for establishing our initial understanding of how the signature works, clinical use of the 
signature would ideally be able to determine HNF4a activity based on the information contained 
in a single sample. Preliminary work done by the bioinformatics core has identified multiple 
internal reference genes for each of the 44 signature genes, and machine learning techniques 
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have been used to quantify HNF4a activity based on the relationships between each signature 
gene and its reference genes. This is a promising approach which could lead to practical clinical 
application. 
 
5.3. Hepatic HNF4a in Systemic Metabolism and Energetics 
Our understanding of the role of HNF4a in metabolism has been limited to its effects on the liver 
and serum chemistries. Deletion of HNF4a causes hepatic steatosis by decreasing hepatic lipid 
export and increasing hepatic lipid import while depletion of hepatic glycogen occurs through 
inhibited hepatic gluconeogenesis. These observations are adequate for understanding HNF4a’s 
role in hepatic metabolism, but its broader impact on systemic metabolism is not as well 
understood. The studies performed using indirect calorimetry have demonstrated how metabolic 
regulation by hepatic HNF4a is central to energy homeostasis and how disruption of HNF4a has 
significant consequences for metabolism in the entire organism.  
 
Hypoglycemia and transient hepatic steatosis are well-known metabolic changes which occur 
after PH (J. Huang & Rudnick, 2014), but countering either can lead to inhibited liver 
regeneration. Several studies have shown that inhibiting hepatic steatosis after PH reduces 
hepatocyte proliferation (Fernandez et al., 2006; Kohjima et al., 2013; Shteyer et al., 2004) 
because accumulation of hepatic triglycerides is required to fuel b-oxidation in the regenerating 
liver (Bellet et al., 2016; Kachaylo et al., 2017; Kohjima et al., 2013; Mukherjee et al., 2017). 
Studies have also shown that inhibition of transient steatosis impairs liver regeneration by 
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increasing expression of the HNF4a target gene p21 (Gazit et al., 2010; Weymann et al., 2009). 
These lipids come from lipolysis of adipose depots, and regeneration in lipid dystrophic mice 
which have decreased adipose stores, exhibit decreased hepatic steatosis and impaired liver 
regeneration (Gazit et al., 2010). This lipolysis is triggered by hypoglycemia, and 
supplementation with dextrose or glucose inhibits liver regeneration (Caruana et al., 1986; 
Weymann et al., 2009). Only one study has used indirect calorimetry to examine liver 
regeneration after PH (Kachaylo et al., 2017). This dissertation has demonstrated the role of 
HNF4a in liver regeneration and has uncovered significant effects on energy expenditure 
following hepatic HNF4a deletion. Future studies will use indirect calorimetry and other 
techniques to examine how HNF4a regulates metabolism during liver regeneration. 
 
Endoplasmic Reticulum (ER) stress is known to cause hepatic steatosis and reduced serum lipids 
(Rutkowski et al., 2008; Yamamoto et al., 2010; Zhang et al., 2011). ER stress-induced hepatic 
steatosis involves changes in the expression of many genes involved in lipid metabolism. ER 
stress can downregulate HNF4a which decreases expression of b-oxidation and VLDL genes 
(Arensdorf, Dezwaan McCabe, Kaufman, & Rutkowski, 2013; Piccolo et al., 2017). Decreased 
b-oxidation and VLDL secretion contributes to fatty liver during early ER stress, but with 
prolonged ER stress, mice become hypoglycemic and increased adipose lipolysis becomes a 
major contributor to hepatic steatosis (DeZwaan-McCabe et al., 2017). This phenotype 
(decreased b-oxidation, decreased VLDL secretion, hypoglycemia, increased adipose lipolysis) 
is very similar to what we observed in HNF4a-KO mice. Knowing the role decreased HNF4a 
plays in progression of liver disease, it would be interesting to examine if similar mechanisms 
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drive mouse models of liver disease. Indirect calorimetry analysis would allow us to test if 
interventions to restore metabolic homeostasis can reverse or attenuate these diseases, or 
improve survival. Already it has been shown in mice that increased b-oxidation following fibrate 
treatment increases energy expenditure and prevents hepatic steatosis, despite higher ER stress 
(Chan et al., 2013). In humans, L-carnitine supplementation in cirrhotic patients exhibiting 
protein-energy malnutrition, can improve respiratory quotient values (Sakai et al., 2016), a 
marker with prognostic value (H. Nishikawa et al., 2017). Indirect calorimetry would allow us to 
investigate how disruptions in HNF4a-regulated metabolism contributes to these diseases. 
 
Finally, chemicals known as perfluoroalkyl acids are known to cause hepatic steatosis and are 
capable of targeting HNF4a (Beggs et al., 2016). These compounds are also known to produce 
some obesogenic effects (Domazet, Grontved, Timmermann, Nielsen, & Jensen, 2016; Liu et al., 
2018). While the toxic effects of compounds are often described by their effects on individual 
tissues, indirect calorimetry would allow us to determine if the net toxic effects of a chemical 
would be likely to cause obesity by creating a long term positive energy balance.  
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